1
|
Abid I, Moslah W, Cojean S, Imbert N, Loiseau PM, Chamayou A, Srairi-Abid N, Calvet R, Baltas M. The Synthesis of 2'-Hydroxychalcones under Ball Mill Conditions and Their Biological Activities. Molecules 2024; 29:1819. [PMID: 38675640 PMCID: PMC11054009 DOI: 10.3390/molecules29081819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Revised: 04/10/2024] [Accepted: 04/12/2024] [Indexed: 04/28/2024] Open
Abstract
Chalcones are polyphenols that belong to the flavonoids family, known for their broad pharmacological properties. They have thus attracted the attention of chemists for their obtention and potential activities. In our study, a library of compounds from 2'-hydroxychalcone's family was first synthesized. A one-step mechanochemical synthesis via Claisen-Schmidt condensation reaction under ball mill conditions was studied, first in a model reaction between a 5'-fluoro-2'-hydroxyacetophenone and 3,4-dimethoxybenzaldehyde. The reaction was optimized in terms of catalysts, ratio of reagents, reaction time, and influence of additives. Among all assays, we retained the best one, which gave the highest yield of 96% when operating in the presence of 1 + 1 eq. of substituted benzaldehyde and 2 eq. of KOH under two grinding cycles of 30 min. Thus, this protocol was adopted for the synthesis of the selected library of 2'-hydroxychalcones derivatives. The biological activities of 17 compounds were then assessed against Plasmodium falciparum, Leishmania donovani parasite development, as well as IGR-39 melanoma cell lines by inhibiting their viability and proliferation. Compounds 6 and 11 are the most potent against L. donovani, exhibiting IC50 values of 2.33 µM and 2.82 µM, respectively, better than the reference drug Miltefosine (3.66 µM). Compound 15 presented the most interesting antimalarial activity against the 3D7 strain, with IC50 = 3.21 µM. Finally, chalcone 12 gave the best result against IGR-39 melanoma cell lines, with an IC50 value of 12 µM better than the reference drug Dacarbazine (IC50 = 25 µM).
Collapse
Affiliation(s)
- Imen Abid
- LCC (Laboratoire de Chimie de Coordination), UPR CNRS 8241, Université de Toulouse, UPS, INPT, Inserm ERL 1289, 205 Route de Narbonne, BP 44099, CEDEX 4, F-31077 Toulouse, France;
- Centre RAPSODEE (Recherche d’Albi en génie des Procédés des SOlides Divisés, de l’Energie et de l’Environnement), IMT Mines Albi, UMR CNRS 5302, Université de Toulouse, Campus Jarlard, Allée des Sciences, CEDEX 09, F-81013 Albi, France;
| | - Wassim Moslah
- Laboratoire des Biomolecules, Venins et Applications Théranostiques (LR20IPT01), Institut Pasteur de Tunis, Université Tunis-ElManar, Tunis 1002, Tunisia; (W.M.); (N.S.-A.)
| | - Sandrine Cojean
- BioCIS (Biomolécules: Conception, Isolement et Synthèse), UMR CNRS 8076, Université Paris-Saclay, F-91400 Orsay, France; (S.C.); (N.I.); (P.M.L.)
- National Malaria Reference Centre, AP-HP, Hôpital Bichat—Claude Bernard, 46 Rue Henri Huchard, F-75018 Paris, France
| | - Nicolas Imbert
- BioCIS (Biomolécules: Conception, Isolement et Synthèse), UMR CNRS 8076, Université Paris-Saclay, F-91400 Orsay, France; (S.C.); (N.I.); (P.M.L.)
| | - Philippe M. Loiseau
- BioCIS (Biomolécules: Conception, Isolement et Synthèse), UMR CNRS 8076, Université Paris-Saclay, F-91400 Orsay, France; (S.C.); (N.I.); (P.M.L.)
| | - Alain Chamayou
- Centre RAPSODEE (Recherche d’Albi en génie des Procédés des SOlides Divisés, de l’Energie et de l’Environnement), IMT Mines Albi, UMR CNRS 5302, Université de Toulouse, Campus Jarlard, Allée des Sciences, CEDEX 09, F-81013 Albi, France;
| | - Najet Srairi-Abid
- Laboratoire des Biomolecules, Venins et Applications Théranostiques (LR20IPT01), Institut Pasteur de Tunis, Université Tunis-ElManar, Tunis 1002, Tunisia; (W.M.); (N.S.-A.)
| | - Rachel Calvet
- Centre RAPSODEE (Recherche d’Albi en génie des Procédés des SOlides Divisés, de l’Energie et de l’Environnement), IMT Mines Albi, UMR CNRS 5302, Université de Toulouse, Campus Jarlard, Allée des Sciences, CEDEX 09, F-81013 Albi, France;
| | - Michel Baltas
- LCC (Laboratoire de Chimie de Coordination), UPR CNRS 8241, Université de Toulouse, UPS, INPT, Inserm ERL 1289, 205 Route de Narbonne, BP 44099, CEDEX 4, F-31077 Toulouse, France;
| |
Collapse
|
2
|
Gendron T, Lanfranchi DA, Wenzel NI, Kessedjian H, Jannack B, Maes L, Cojean S, Müller TJJ, Loiseau PM, Davioud-Charvet E. Chemoselective Synthesis and Anti-Kinetoplastidal Properties of 2,6-Diaryl-4 H-tetrahydro-thiopyran-4-one S-Oxides: Their Interplay in a Cascade of Redox Reactions from Diarylideneacetones. Molecules 2024; 29:1620. [PMID: 38611899 PMCID: PMC11013284 DOI: 10.3390/molecules29071620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2024] [Revised: 03/26/2024] [Accepted: 04/01/2024] [Indexed: 04/14/2024] Open
Abstract
2,6-Diaryl-4H-tetrahydro-thiopyran-4-ones and corresponding sulfoxide and sulfone derivatives were designed to lower the major toxicity of their parent anti-kinetoplatidal diarylideneacetones through a prodrug effect. Novel diastereoselective methodologies were developed and generalized from diarylideneacetones and 2,6-diaryl-4H-tetrahydro-thiopyran-4-ones to allow the introduction of a wide substitution profile and to prepare the related S-oxides. The in vitro biological activity and selectivity of diarylideneacetones, 2,6-diaryl-4H-tetrahydro-thiopyran-4-ones, and their S-sulfoxide and sulfone metabolites were evaluated against Trypanosoma brucei brucei, Trypanosoma cruzi, and various Leishmania species in comparison with their cytotoxicity against human fibroblasts hMRC-5. The data revealed that the sulfides, sulfoxides, and sulfones, in which the Michael acceptor sites are temporarily masked, are less toxic against mammal cells while the anti-trypanosomal potency was maintained against T. b. brucei, T. cruzi, L. infantum, and L. donovani, thus confirming the validity of the prodrug strategy. The mechanism of action is proposed to be due to the involvement of diarylideneacetones in cascades of redox reactions involving the trypanothione system. After Michael addition of the dithiol to the double bonds, resulting in an elongated polymer, the latter-upon S-oxidation, followed by syn-eliminations-fragments, under continuous release of reactive oxygen species and sulfenic/sulfonic species, causing the death of the trypanosomal parasites in the micromolar or submicromolar range with high selectivity indexes.
Collapse
Affiliation(s)
- Thibault Gendron
- UMR7042 Université de Strasbourg–CNRS–UHA, Laboratoire d’Innovation Moléculaire et Applications (LIMA), Team Bio(IN)organic and Medicinal Chemistry, European School of Chemistry, Polymers and Materials (ECPM), 25 Rue Becquerel, F-67087 Strasbourg, France; (T.G.); (D.A.L.); (H.K.)
| | - Don Antoine Lanfranchi
- UMR7042 Université de Strasbourg–CNRS–UHA, Laboratoire d’Innovation Moléculaire et Applications (LIMA), Team Bio(IN)organic and Medicinal Chemistry, European School of Chemistry, Polymers and Materials (ECPM), 25 Rue Becquerel, F-67087 Strasbourg, France; (T.G.); (D.A.L.); (H.K.)
| | - Nicole I. Wenzel
- Bioorganic & Medicinal Chemistry Laboratory, Biochemie-Zentrum, Heidelberg University, Im Neuenheimer Feld 504, D-69120 Heidelberg, Germany; (N.I.W.)
| | - Hripsimée Kessedjian
- UMR7042 Université de Strasbourg–CNRS–UHA, Laboratoire d’Innovation Moléculaire et Applications (LIMA), Team Bio(IN)organic and Medicinal Chemistry, European School of Chemistry, Polymers and Materials (ECPM), 25 Rue Becquerel, F-67087 Strasbourg, France; (T.G.); (D.A.L.); (H.K.)
| | - Beate Jannack
- Bioorganic & Medicinal Chemistry Laboratory, Biochemie-Zentrum, Heidelberg University, Im Neuenheimer Feld 504, D-69120 Heidelberg, Germany; (N.I.W.)
| | - Louis Maes
- Laboratory of Microbiology, Parasitology and Hygiene (LMPH), Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium;
| | - Sandrine Cojean
- Antiparasitic Chemotherapy, Faculty of Pharmacy, BioCIS, UMR 8076 Université Paris-Saclay-CNRS 17, Rue des Sciences, F-91400 Orsay, France; (S.C.); (P.M.L.)
| | - Thomas J. J. Müller
- Institut für Organische Chemie und Makromolekulare Chemie, Mathematisch-Naturwissenschaftliche FakultätFakultät, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, D-40225 Düsseldorf, Germany;
| | - Philippe M. Loiseau
- Antiparasitic Chemotherapy, Faculty of Pharmacy, BioCIS, UMR 8076 Université Paris-Saclay-CNRS 17, Rue des Sciences, F-91400 Orsay, France; (S.C.); (P.M.L.)
| | - Elisabeth Davioud-Charvet
- UMR7042 Université de Strasbourg–CNRS–UHA, Laboratoire d’Innovation Moléculaire et Applications (LIMA), Team Bio(IN)organic and Medicinal Chemistry, European School of Chemistry, Polymers and Materials (ECPM), 25 Rue Becquerel, F-67087 Strasbourg, France; (T.G.); (D.A.L.); (H.K.)
| |
Collapse
|
3
|
Obeid S, Berbel-Manaia E, Nicolas V, Dennemont I, Barbier J, Cintrat JC, Gillet D, Loiseau PM, Pomel S. Deciphering the mechanism of action of VP343, an antileishmanial drug candidate, in Leishmania infantum. iScience 2023; 26:108144. [PMID: 37915600 PMCID: PMC10616420 DOI: 10.1016/j.isci.2023.108144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 07/25/2023] [Accepted: 10/02/2023] [Indexed: 11/03/2023] Open
Abstract
Antileishmanial chemotherapy is currently limited due to severe toxic side effects and drug resistance. Hence, new antileishmanial compounds based on alternative approaches, mainly to avoid the emergence of drug resistance, are needed. The present work aims to decipher the mechanism of action of an antileishmanial drug candidate, named VP343, inhibiting intracellular Leishmania infantum survival via the host cell. Cell imaging showed that VP343 interferes with the fusion of parasitophorous vacuoles and host cell late endosomes and lysosomes, leading to lysosomal cholesterol accumulation and ROS overproduction within host cells. Proteomic analyses showed that VP343 perturbs host cell vesicular trafficking as well as cholesterol synthesis/transport pathways. Furthermore, a knockdown of two selected targets involved in vesicle-mediated transport, Pik3c3 and Sirt2, resulted in similar antileishmanial activity to VP343 treatment. This work revealed potential host cell pathways and targets altered by VP343 that would be of interest for further development of host-directed antileishmanial drugs.
Collapse
Affiliation(s)
- Sameh Obeid
- Université Paris-Saclay, CNRS BioCIS, 91400 Orsay, France
| | | | - Valérie Nicolas
- Université Paris-Saclay, UMS-IPSIT, Microscopy Facility, 92019 Châtenay-Malabry, France
| | | | - Julien Barbier
- Université Paris-Saclay, UMS-IPSIT, Microscopy Facility, 92019 Châtenay-Malabry, France
| | - Jean-Christophe Cintrat
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France
| | - Daniel Gillet
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191 Gif-sur-Yvette, France
| | | | | |
Collapse
|
4
|
Lachhab S, El Mansouri AE, Mehdi A, Dennemont I, Neyts J, Jochmans D, Andrei G, Snoeck R, Sanghvi YS, Ait Ali M, Loiseau PM, Lazrek HB. Synthesis of new 3-acetyl-1,3,4-oxadiazolines combined with pyrimidines as antileishmanial and antiviral agents. Mol Divers 2023; 27:2147-2159. [PMID: 36251201 PMCID: PMC9573813 DOI: 10.1007/s11030-022-10548-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2022] [Accepted: 10/07/2022] [Indexed: 11/25/2022]
Abstract
A new series of 3-acetyl-1,3,4-oxadiazoline hybrid molecules was designed and synthesized using a condensation between acyclonucleosides and substituted phenylhydrazone. All intermediates and final products were screened against Leishmania donovani, a Protozoan parasite and against three viruses SARS-CoV-2, HCMV and VZV. While no significant activity was observed against the viruses, the intermediate with 6-azatymine as thymine and 5-azathymine-3-acetyl-1,3,4-oxadiazoline hybrid exhibited a significant antileishmanial activity. The later compound was the most promising, exhibiting an IC50 value at 8.98 µM on L. donovani intramacrophage amastigotes and a moderate selectivity index value at 2.4.
Collapse
Affiliation(s)
- Saida Lachhab
- Laboratory of Biomolecular and Medicinal Chemistry, Faculty of Science Semlalia, University Cadi Ayyad, Marrakech, Morocco
| | - Az-Eddine El Mansouri
- Department of Chemistry, University of the Free State, P.O. Box 339, Bloemfontein, 9300, South Africa
| | - Ahmad Mehdi
- ICGM, Université Montpellier, CNRS, ENSCM, Montpellier, France
| | - Indira Dennemont
- Antiparasite Chemotherapy, CNRS, BioCIS, Université Paris-Saclay, Chatenay-Malabry, 92290, Paris, France
| | - Johan Neyts
- Rega Institute for Medical Research, KULeuven, Louvain, Belgium
| | - Dirk Jochmans
- Rega Institute for Medical Research, KULeuven, Louvain, Belgium
| | - Graciela Andrei
- Rega Institute for Medical Research, KULeuven, Louvain, Belgium
| | - Robert Snoeck
- Rega Institute for Medical Research, KULeuven, Louvain, Belgium
| | - Yogesh S Sanghvi
- Rasayan Inc., 2802 Crystal Ridge Road, Encinitas, CA, 92024-6615, USA
| | - Mustapha Ait Ali
- Laboratory of Biomolecular and Medicinal Chemistry, Faculty of Science Semlalia, University Cadi Ayyad, Marrakech, Morocco
| | - Philippe M Loiseau
- Antiparasite Chemotherapy, CNRS, BioCIS, Université Paris-Saclay, Chatenay-Malabry, 92290, Paris, France
| | - Hassan B Lazrek
- Laboratory of Biomolecular and Medicinal Chemistry, Faculty of Science Semlalia, University Cadi Ayyad, Marrakech, Morocco.
| |
Collapse
|
5
|
Demicheli C, Vallejos VMR, Lanza JS, Ramos GS, Do Prado BR, Pomel S, Loiseau PM, Frézard F. Supramolecular assemblies from antimony(V) complexes for the treatment of leishmaniasis. Biophys Rev 2023; 15:751-765. [PMID: 37681109 PMCID: PMC10480371 DOI: 10.1007/s12551-023-01073-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 05/30/2023] [Indexed: 09/09/2023] Open
Abstract
The pentavalent meglumine antimoniate (MA) is still a first-line drug in the treatment of leishmaniasis in several countries. As an attempt to elucidate its mechanism of action and develop new antimonial drugs with improved therapeutic profile, Sb(V) complexes with different ligands, including β-cyclodextrin (β-CD), nucleosides and non-ionic surfactants, have been studied. Interestingly, Sb(V) oxide, MA, its complex with β-CD, Sb(V)-guanosine complex and amphiphilic Sb(V) complexes with N-alkyl-N-methylglucamide, have shown marked tendency to self-assemble in aqueous solutions, forming nanoaggregates, hydrogel or micelle-like nanoparticles. Surprisingly, the resulting assemblies presented in most cases slow dissociation kinetics upon dilution and a strong influence of pH, which impacted on their pharmacokinetic and therapeutic properties against leishmaniasis. To explain this unique property, we raised the hypothesis that multiple pnictogen bonds could contribute to the formation of these assemblies and their kinetic of dissociation. The present article reviews our current knowledge on the structural organization and physicochemical characteristics of Sb-based supramolecular assemblies, as well as their pharmacological properties and potential for treatment of leishmaniasis. This review supports the feasibility of the rational design of new Sb(V) complexes with supramolecular assemblies for the safe and effective treatment of leishmaniasis.
Collapse
Affiliation(s)
- Cynthia Demicheli
- Department of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil
| | - Virgínia M. R. Vallejos
- Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil
| | | | - Guilherme S. Ramos
- Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil
| | - Bruno R. Do Prado
- Department of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil
| | - Sébastien Pomel
- Faculty of Pharmacy, Antiparasite Chemotherapy (PARACHEM), UMR 8076 CNRS BioCIS, University Paris-Saclay, 91400 Orsay, France
| | - Philippe M. Loiseau
- Faculty of Pharmacy, Antiparasite Chemotherapy (PARACHEM), UMR 8076 CNRS BioCIS, University Paris-Saclay, 91400 Orsay, France
| | - Frédéric Frézard
- Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901 Brazil
| |
Collapse
|
6
|
Seck I, Ciss I, Diédhiou A, Baldé M, Ka S, Ba LA, Ndoye SF, Figadère B, Seon-Meniel B, Gomez G, Cojean S, Pomel S, Loiseau PM, Fall Y, Seck M. 1,2,3-triazenes and 1,2,3-triazoles as antileishmanial, antitrypanosomal, and antiplasmodial agents. Med Chem Res 2022. [DOI: 10.1007/s00044-022-02994-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
7
|
Koumpoura C, Nguyen M, Bijani C, Vendier L, Salina EG, Buroni S, Degiacomi G, Cojean S, Loiseau PM, Benoit-Vical F, García-Sosa AT, Baltas M. Design of Anti-infectious Agents from Lawsone in a Three-Component Reaction with Aldehydes and Isocyanides. ACS Omega 2022; 7:35635-35655. [PMID: 36249398 PMCID: PMC9558256 DOI: 10.1021/acsomega.2c03421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 09/07/2022] [Indexed: 06/16/2023]
Abstract
The first effective synthetic approach to naphthofuroquinones via a reaction involving lawsone, various aldehydes, and three isocyanides under microwave irradiation afforded derivatives in moderate to good yields. In addition, for less-reactive aldehydes, two naphtho-enaminodione quinones were obtained for the first time, as result of condensation between lawsone and isocyanides. X-ray structure determination for 9 and 2D-NMR spectra of 28 confirmed the obtained structures. All compounds were evaluated for their anti-infectious activities against Plasmodium falciparum, Leishmania donovani, and Mycobacterium tuberculosis. Among the naphthofuroquinone series, 17 exhibited comparatively the best activity against P. falciparum (IC50 = 2.5 μM) and M. tuberculosis (MIC = 9 μM) with better (P. falciparum) or equivalent (M. tuberculosis) values to already-known naphthofuroquinone compounds. Among the two naphtho-enaminodione quinones, 28 exhibited a moderate activity against P. falciparum with a good selectivity index (SI > 36) while also a very high potency against L. donovani (IC50 = 3.5 μM and SI > 28), rendering it very competitive to the reference drug miltefosine. All compounds were studied through molecular modeling on their potential targets for P. falciparum, Pfbc1, and PfDHODH, where 17 showed the most favorable interactions.
Collapse
Affiliation(s)
- Christina
L. Koumpoura
- Laboratoire
de Chimie de Coordination du CNRS−UPR8241, Inserm ERL 1289
Team “New antiplasmodial molecules and pharmacological approaches”, 205 route de Narbonne, BP 44099, Toulouse Cedex 31077, France
| | - Michel Nguyen
- Laboratoire
de Chimie de Coordination du CNRS−UPR8241, Inserm ERL 1289
Team “New antiplasmodial molecules and pharmacological approaches”, 205 route de Narbonne, BP 44099, Toulouse Cedex 31077, France
| | - Christian Bijani
- Laboratoire
de Chimie de Coordination du CNRS−UPR8241, Inserm ERL 1289
Team “New antiplasmodial molecules and pharmacological approaches”, 205 route de Narbonne, BP 44099, Toulouse Cedex 31077, France
| | - Laure Vendier
- Laboratoire
de Chimie de Coordination du CNRS−UPR8241, Inserm ERL 1289
Team “New antiplasmodial molecules and pharmacological approaches”, 205 route de Narbonne, BP 44099, Toulouse Cedex 31077, France
| | - Elena G. Salina
- Bach
Institute of Biochemistry, Research Center
of Biotechnology of the Russian Academy of Sciences, Moscow 119071, Russia
| | - Silvia Buroni
- Department
of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, Pavia 27100, Italy
| | - Giulia Degiacomi
- Department
of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, Pavia 27100, Italy
| | - Sandrine Cojean
- Antiparasite
Chemotherapy, UMR 8076 CNRS BioCIS, Faculty of Pharmacy, University
Paris-Saclay, Châtenay-Malabry 92290, France
| | - Philippe M. Loiseau
- Antiparasite
Chemotherapy, UMR 8076 CNRS BioCIS, Faculty of Pharmacy, University
Paris-Saclay, Châtenay-Malabry 92290, France
| | - Françoise Benoit-Vical
- Laboratoire
de Chimie de Coordination du CNRS−UPR8241, Inserm ERL 1289
Team “New antiplasmodial molecules and pharmacological approaches”, 205 route de Narbonne, BP 44099, Toulouse Cedex 31077, France
| | - Alfonso T. García-Sosa
- Department
of Molecular Technology, Institute of Chemistry, University of Tartu, Ravila 14a, Tartu 50411, Estonia
| | - Michel Baltas
- Laboratoire
de Chimie de Coordination du CNRS−UPR8241, Inserm ERL 1289
Team “New antiplasmodial molecules and pharmacological approaches”, 205 route de Narbonne, BP 44099, Toulouse Cedex 31077, France
| |
Collapse
|
8
|
Fechtali-Moute Z, Loiseau PM, Pomel S. Stimulation of Acanthamoeba castellanii excystment by enzyme treatment and consequences on trophozoite growth. Front Cell Dev Biol 2022; 10:982897. [PMID: 36172275 PMCID: PMC9511172 DOI: 10.3389/fcell.2022.982897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Accepted: 08/17/2022] [Indexed: 11/13/2022] Open
Abstract
Acanthamoeba castellanii is a widespread Free-Living Amoeba (FLA) that can cause severe ocular or cerebral infections in immunocompetent and immunocompromised patients, respectively, besides its capacity to transport diverse pathogens. During their life cycle, FLA can alternate between a vegetative form, called a trophozoite, and a latent and resistant form, called a cyst. This resistant form is characterized by the presence of a cell wall containing two layers, namely the ectocyst and the endocyst, mainly composed of cellulose and proteins. In the present work, we aimed to stimulate Acanthamoeba castellanii excystment by treating their cysts with a cellulolytic enzyme, i.e., cellulase, or two proteolytic enzymes, i.e., collagenase and pepsin. While 11 days were necessary to obtain total excystment in the control at 27°C, only 48 h were sufficient at the same temperature to obtain 100% trophozoites in the presence of 25 U/mL cellulase, 50 U/mL collagenase or 100 U/mL pepsin. Additionally, more than 96% amoebae have excysted after only 24 h with 7.5 U/mL cellulase at 30°C. Nevertheless, no effect of the three enzymes was observed on the excystment of Balamuthia mandrillaris and Vermamoeba vermiformis. Surprisingly, A. castellanii trophozoites excysted in the presence of cellulase displayed a markedly shorter doubling time at 7 h, in comparison to the control at 23 h. Likewise, trophozoites doubled their population in 9 h when both cellulose and cellulase were added to the medium, indicating that Acanthamoeba cyst wall degradation products promote their trophozoite proliferation. The analysis of cysts in epifluorescent microscopy using FITC-lectins and in electron microscopy revealed a disorganized endocyst and a reduction of the intercystic space area after cellulase treatment, implying that these cellular events are preliminary to trophozoite release during excystment. Further studies would be necessary to determine the signaling pathways involved during this amoebal differentiation process to identify new therapeutic targets for the development of anti-acanthamoebal drugs.
Collapse
|
9
|
Lipa Castro A, Pomel S, Cailleau C, Fournier N, Dennemont I, Loiseau PM, Barratt G. Pharmacokinetics, biodistribution, and activity of Amphotericin B-loaded nanocochleates on the Leishmania donovani murine visceral leishmaniasis model. Int J Pharm 2022; 624:121985. [PMID: 35820519 DOI: 10.1016/j.ijpharm.2022.121985] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Revised: 06/15/2022] [Accepted: 07/02/2022] [Indexed: 12/11/2022]
Abstract
Amphotericin B (AmB) is an effective drug to treat visceral leishmaniasis but its use is limited by its poor oral bioavailability. This article describes the in-vivo evaluation of AmB-loaded, lipid-based cochleate systems designed for the oral route. Two different cochleate formulations were studied: one based on the synthetic phospholipid dioleoylphosphatidylserine (DOPS) and another optimized formulation based on a naturally occurring phosphatidylserine (Lipoid PSP70) that would render the formulation more affordable in developing countries. Their antiparasitic activity was evaluated in a mouse model of visceral leishmaniasis. Limited efficacy was observed for the DOPS-based cochleates after three doses of AmB at 1 mg/kg. The Lipoid PSP70-based cochleates were administered either as a buffered suspension or in enteric-coated capsules. AmB-loaded cochleates administered as a suspension at a high dose (3 × 20 mg/kg) exhibited significant antiparasitic activity while AmB-loaded cochleates in enteric-coated capsules at a lower dose (3 × 5 mg/kg) presented a slightly higher significant activity. A pharmacokinetic and biodistribution study in rats was performed with the Lipoid PSP70-based cochleates, with a single oral dose of 7.5 mg AmB/kg. Cochleates in both administration forms led to lower concentrations of Amphotericin B in the plasma than intravenous AmBisome®. However, more accumulation in the organs of interest (liver, spleen) was observed for both presentations of cochleates than for AmBisome® by the oral route. Therefore, cochleate formulations of AmB that could be produced at a cost accessible for developing countries show promise for the treatment of visceral leishmaniasis.
Collapse
Affiliation(s)
- Antonio Lipa Castro
- Institut Galien Paris-Saclay, UMR CNRS 8612, Faculty of Pharmacy, Univ. Paris-Saclay, Bâtiment Henri MOISSAN, 17 avenue des Sciences, 91400 Orsay, France
| | - Sébastien Pomel
- BioCIS, UMR CNRS 8076, Faculty of Pharmacy, Univ. Paris-Saclay, Bâtiment Henri MOISSAN, 17 avenue des Sciences, 91400 Orsay, France
| | - Catherine Cailleau
- Institut Galien Paris-Saclay, UMR CNRS 8612, Faculty of Pharmacy, Univ. Paris-Saclay, Bâtiment Henri MOISSAN, 17 avenue des Sciences, 91400 Orsay, France
| | - Natalie Fournier
- Biochemistry Laboratory, Georges Pompidou European Hospital, AP-HP, Paris, France; Lip(Sys)2-EA7357, Atherosclerosis and Macrophages: Impact of Phospholipids and Mitochondrial Function on Cellular Cholesterol Efflux, Faculty of Pharmacy, Univ. Paris-Saclay, Bâtiment Henri MOISSAN, 17 avenue des Sciences, 91400 Orsay, France
| | - Indira Dennemont
- BioCIS, UMR CNRS 8076, Faculty of Pharmacy, Univ. Paris-Saclay, Bâtiment Henri MOISSAN, 17 avenue des Sciences, 91400 Orsay, France
| | - Philippe M Loiseau
- BioCIS, UMR CNRS 8076, Faculty of Pharmacy, Univ. Paris-Saclay, Bâtiment Henri MOISSAN, 17 avenue des Sciences, 91400 Orsay, France
| | - Gillian Barratt
- Institut Galien Paris-Saclay, UMR CNRS 8612, Faculty of Pharmacy, Univ. Paris-Saclay, Bâtiment Henri MOISSAN, 17 avenue des Sciences, 91400 Orsay, France
| |
Collapse
|
10
|
Ramos GS, Vallejos VMR, Borges GSM, Almeida RM, Alves IM, Aguiar MMG, Fernandes C, Guimarães PPG, Fujiwara RT, Loiseau PM, Ferreira LAM, Frézard F. Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes. Pharmaceutics 2022; 14:pharmaceutics14050989. [PMID: 35631575 PMCID: PMC9147047 DOI: 10.3390/pharmaceutics14050989] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 04/25/2022] [Accepted: 04/25/2022] [Indexed: 11/16/2022] Open
Abstract
Liposomal amphotericin B (AmB) or AmBisome® is the most effective and safe therapeutic agent for visceral leishmaniasis (VL), but its clinical efficacy is limited in cutaneous leishmaniasis (CL) and HIV/VL co-infection. The aim of this work was to develop a formulation of AmB in PEGylated liposomes and compare its efficacy to AmBisome® in a murine model of CL. Formulations of AmB in conventional and PEGylated liposomes were characterized for particle size and morphology, drug encapsulation efficiency and aggregation state. Those were compared to AmBisome® in Leishmania amazonensis-infected BALB/c mice for their effects on the lesion size growth and parasite load. The conventional and PEGylated formulations showed vesicles with 100–130 nm diameter and low polydispersity, incorporating more than 95% of AmB under the non-aggregated form. Following parenteral administration in the murine model of CL, the PEGylated formulation of AmB significantly reduced the lesion size growth and parasite load, in comparison to control groups, in contrast to conventional liposomal AmB. The PEGylated formulation of AmB was also effective when given by oral route on a 2-day regimen. This work reports for the first time that PEGylated liposomal AmB can improve the treatment of experimental cutaneous leishmaniasis by both parenteral and oral routes.
Collapse
Affiliation(s)
- Guilherme S. Ramos
- Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil; (G.S.R.); (V.M.R.V.); (P.P.G.G.)
| | - Virgínia M. R. Vallejos
- Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil; (G.S.R.); (V.M.R.V.); (P.P.G.G.)
| | - Gabriel S. M. Borges
- Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil; (G.S.M.B.); (I.M.A.); (M.M.G.A.); (C.F.); (L.A.M.F.)
| | - Raquel M. Almeida
- Department of Parasitology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil; (R.M.A.); (R.T.F.)
| | - Izabela M. Alves
- Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil; (G.S.M.B.); (I.M.A.); (M.M.G.A.); (C.F.); (L.A.M.F.)
| | - Marta M. G. Aguiar
- Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil; (G.S.M.B.); (I.M.A.); (M.M.G.A.); (C.F.); (L.A.M.F.)
| | - Christian Fernandes
- Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil; (G.S.M.B.); (I.M.A.); (M.M.G.A.); (C.F.); (L.A.M.F.)
| | - Pedro P. G. Guimarães
- Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil; (G.S.R.); (V.M.R.V.); (P.P.G.G.)
| | - Ricardo T. Fujiwara
- Department of Parasitology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil; (R.M.A.); (R.T.F.)
| | - Philippe M. Loiseau
- Faculty of Pharmacy, Antiparasite Chemotherapy, UMR 8076 CNRS BioCIS, University Paris-Saclay, F-92296 Chatenay-Malabry, France;
| | - Lucas A. M. Ferreira
- Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil; (G.S.M.B.); (I.M.A.); (M.M.G.A.); (C.F.); (L.A.M.F.)
| | - Frédéric Frézard
- Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil; (G.S.R.); (V.M.R.V.); (P.P.G.G.)
- Correspondence: ; Tel.: +55-31-34092940
| |
Collapse
|
11
|
Batista AS, Oliveira SDS, Pomel S, Commere PH, Mazan V, Lee M, Loiseau PM, Rossi-Bergmann B, Prina E, Duval R. Targeting chalcone binding sites in living Leishmania using a reversible fluorogenic benzochalcone probe. Biomed Pharmacother 2022; 149:112784. [PMID: 35299122 DOI: 10.1016/j.biopha.2022.112784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Revised: 02/28/2022] [Accepted: 03/02/2022] [Indexed: 11/17/2022] Open
Abstract
Chalcones (1,3-diphenyl-2-propen-1-ones) either natural or synthetic have a plethora of biological properties including antileishmanial activities, but their development as drugs is hampered by their largely unknown mechanisms of action. We demonstrate herein that our previously described benzochalcone fluorogenic probe (HAB) could be imaged by fluorescence microscopy in live Leishmania amazonensis promastigotes where it targeted the parasite acidocalcisomes, lysosomes and the mitochondrion. As in the live zebrafish model, HAB formed yellow-emitting fluorescent complexes when associated with biological targets in Leishmania. Further, we used HAB as a reversible probe to study the binding of a portfolio of diverse chalcones and analogues in live promastigotes, using a combination of competitive flow cytometry analysis and cell microscopy. This pharmacological evaluation suggested that the binding of HAB in promastigotes was representative of chalcone pharmacology in Leishmania, with certain exogenous chalcones exhibiting competitive inhibition (ca. 20-30%) towards HAB whereas non-chalconic inhibitors showed weak capacity (ca. 3-5%) to block the probe intracellular binding. However, this methodology was restricted by the strong toxicity of several competing chalcones at high concentration, in conjunction with the limited sensitivity of the HAB fluorophore. This advocates for further optimization of this undirect target detection strategy using pharmacophore-derived reversible fluorescent probes.
Collapse
Affiliation(s)
- Ariane S Batista
- Nanotechnology Engineering Program, Instituto Alberto Luiz Coimbra de Pós-Graduação e Pesquisa de Engenharia - COPPE, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-972, Brazil
| | | | - Sébastien Pomel
- Université Paris-Saclay, CNRS, BioCIS, 92296 Châtenay-Malabry, France
| | | | - Valérie Mazan
- Université de Strasbourg, Université de Haute-Alsace, CNRS, LIMA, UMR 7042, ECPM, 25 Rue Becquerel, 67000 Strasbourg, France
| | - Moses Lee
- Department of Chemistry, Georgia State University, Atlanta 30303, USA
| | | | - Bartira Rossi-Bergmann
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal de Rio de Janeiro, 21941-902 Rio de Janeiro, Brazil
| | - Eric Prina
- Institut Pasteur, Unité de Parasitologie Moléculaire et Signalisation, INSERM U1201, Paris, France
| | - Romain Duval
- Université de Paris, IRD, MERIT, F-75006 Paris, France.
| |
Collapse
|
12
|
Loiseau PM, Balaraman K, Barratt G, Pomel S, Durand R, Frézard F, Figadère B. The Potential of 2-Substituted Quinolines as Antileishmanial Drug Candidates. Molecules 2022; 27:molecules27072313. [PMID: 35408712 PMCID: PMC9000572 DOI: 10.3390/molecules27072313] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 03/29/2022] [Accepted: 03/30/2022] [Indexed: 01/27/2023] Open
Abstract
There is a need for new, cost-effective drugs to treat leishmaniasis. A strategy based on traditional medicine practiced in Bolivia led to the discovery of the 2-substituted quinoline series as a source of molecules with antileishmanial activity and low toxicity. This review documents the development of the series from the first isolated natural compounds through several hundred synthetized molecules to an optimized compound exhibiting an in vitro IC50 value of 0.2 µM against Leishmania donovani, and a selectivity index value of 187, together with in vivo activity on the L. donovani/hamster model. Attempts to establish structure–activity relationships are described, as well as studies that have attempted to determine the mechanism of action. For the latter, it appears that molecules of this series act on multiple targets, possibly including the immune system, which could explain the observed lack of drug resistance after in vitro drug pressure. We also show how nanotechnology strategies could valorize these drugs through adapted formulations and how a mechanistic targeting approach could generate new compounds with increased activity.
Collapse
Affiliation(s)
- Philippe M. Loiseau
- Antiparasite Chemotherapy, CNRS, BioCIS, Université Paris-Saclay, 92290 Chatenay-Malabry, France; (S.P.); (R.D.)
- Correspondence:
| | - Kaluvu Balaraman
- Chemistry Department, Georgetown University, 37th and O Streets, Washington, DC 20057, USA;
| | - Gillian Barratt
- Institute Galien Paris-Saclay, CNRS, Université Paris-Saclay, 92290 Chatenay-Malabry, France;
| | - Sébastien Pomel
- Antiparasite Chemotherapy, CNRS, BioCIS, Université Paris-Saclay, 92290 Chatenay-Malabry, France; (S.P.); (R.D.)
| | - Rémy Durand
- Antiparasite Chemotherapy, CNRS, BioCIS, Université Paris-Saclay, 92290 Chatenay-Malabry, France; (S.P.); (R.D.)
| | - Frédéric Frézard
- Department of Physiology and Biophysics-ICB, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil;
| | - Bruno Figadère
- Chimie des Substances Naturelles, CNRS, BioCIS, Université Paris-Saclay, 92290 Chatenay-Malabry, France;
| |
Collapse
|
13
|
Loiseau PM, German M. La leptospirose : une menace sanitaire croissante pour les activités piscicoles et récréatives. Annales Pharmaceutiques Françaises 2022; 80:778-781. [DOI: 10.1016/j.pharma.2022.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 03/20/2022] [Accepted: 04/06/2022] [Indexed: 12/01/2022]
|
14
|
Mao W, Lazar N, van Tilbeurgh H, Loiseau PM, Pomel S. Minor Impact of A258D Mutation on Biochemical and Enzymatic Properties of Leishmania infantum GDP-Mannose Pyrophosphorylase. Microorganisms 2022; 10:microorganisms10020231. [PMID: 35208687 PMCID: PMC8877407 DOI: 10.3390/microorganisms10020231] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Accepted: 01/17/2022] [Indexed: 02/01/2023] Open
Abstract
Background: Leishmaniasis, a vector-borne disease caused by the protozoan parasite from the genus Leishmania, is endemic to tropical and subtropical areas. Few treatments are available against leishmaniasis, with all presenting issues of toxicity, resistance, and/or cost. In this context, the development of new antileishmanial drugs is urgently needed. GDP-mannose pyrophosphorylase (GDP-MP), an enzyme involved in the mannosylation pathway, has been described to constitute an attractive therapeutic target for the development of specific antileishmanial agents. Methods: In this work, we produced, purified, and analyzed the enzymatic properties of the recombinant L. infantum GDP-MP (LiGDP-MP), a single leishmanial GDP-MP that presents mutation of an aspartate instead of an alanine at position 258, which is also the single residue difference with the homolog in L. donovani: LdGDP-MP. Results: The purified LiGDP-MP displayed high substrate and cofactor specificities, a sequential random mechanism of reaction, and the following kinetic constants: Vm at 0.6 µM·min−1, Km from 15–18 µM, kcat from 12.5–13 min−1, and kcat/Km at around 0.8 min−1µM−1. Conclusions: These results show that LiGDP-MP has similar biochemical and enzymatic properties to LdGDP-MP. Further studies are needed to determine the advantage for L. infantum of the A258D residue change in GDP-MP.
Collapse
Affiliation(s)
- Wei Mao
- Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France; (W.M.); (P.M.L.)
| | - Noureddine Lazar
- Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198 Gif-sur-Yvette, France; (N.L.); (H.v.T.)
| | - Herman van Tilbeurgh
- Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198 Gif-sur-Yvette, France; (N.L.); (H.v.T.)
| | - Philippe M. Loiseau
- Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France; (W.M.); (P.M.L.)
| | - Sébastien Pomel
- Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France; (W.M.); (P.M.L.)
- Correspondence:
| |
Collapse
|
15
|
Helou DG, Mauras A, Fasquelle F, Lanza JS, Loiseau PM, Betbeder D, Cojean S. Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis. PLoS Negl Trop Dis 2021; 15:e0009627. [PMID: 34403413 PMCID: PMC8370633 DOI: 10.1371/journal.pntd.0009627] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Accepted: 07/05/2021] [Indexed: 12/27/2022] Open
Abstract
Visceral leishmaniasis is a protozoan disease associated with high fatality rate in developing countries. Although the drug pipeline is constantly improving, available treatments are costly and live-threatening side effects are not uncommon. Moreover, an approved vaccine against human leishmaniasis does not exist yet. Using whole antigens from Leishmania donovani promastigotes (LdAg), we investigated the protective potential of a novel adjuvant-free vaccine strategy. Immunization of mice with LdAg via the intradermal or the intranasal route prior to infection decreases the parasitic burden in primary affected internal organs, including the liver, spleen, and bone marrow. Interestingly, the intranasal route is more efficient than the intradermal route, leading to better parasite clearance and remarkable induction of adaptive immune cells, notably the helper and cytotoxic T cells. In vitro restimulation experiments with Leishmania antigens led to significant IFN-γ secretion by splenocytes; therefore, exemplifying specificity of the adaptive immune response. To improve mucosal delivery and the immunogenic aspects of our vaccine strategy, we used polysaccharide-based nanoparticles (NP) that carry the antigens. The NP-LdAg formulation is remarkably taken up by dendritic cells and induces their maturation in vitro, as revealed by the increased expression of CD80, CD86 and MHC II. Intranasal immunization with NP-LdAg does not improve the parasite clearance in our experimental timeline; however, it does increase the percentage of effector and memory T helper cells in the spleen, suggesting a potential induction of long-term memory. Altogether, this study provides a simple and cost-effective vaccine strategy against visceral leishmaniasis based on LdAg administration via the intranasal route, which could be applicable to other parasitic diseases. Visceral leishmaniasis is a neglected tropical disease caused by specific species of Leishmania parasites that affect internal organs including spleen, liver, and bone marrow. The infective stage called promastigote, is transmitted into the host skin via sandfly bites. Visceral leishmaniasis is usually associated with high mortality rate in poor and developing countries, lacking proper health assistance. Moreover, treatments are expensive while no approved vaccines exist to prevent infection and avoid disease outbreaks. This study suggests an affordable and adjuvant-free vaccine formulation made from the total lysate of promastigotes. Vaccine administration via the intranasal route, ensures a remarkable clearance of Leishmania parasites from the internal organs of infected experimental mice. In particular, intranasal route known to be not invasive, is efficient in inducing adequate immune response against the infective form of the parasite. Further studies are now required to improve this prophylactic vaccine and provide therefore the basis for a promising translational approach.
Collapse
MESH Headings
- Adaptive Immunity
- Adjuvants, Immunologic/administration & dosage
- Administration, Intranasal
- Animals
- Antibodies, Protozoan/blood
- Antigens, Protozoan/administration & dosage
- Antigens, Protozoan/blood
- Antigens, Protozoan/immunology
- Bone Marrow/metabolism
- Bone Marrow/parasitology
- Female
- Immunization
- Interferon-gamma/metabolism
- Leishmania donovani/immunology
- Leishmaniasis Vaccines/administration & dosage
- Leishmaniasis Vaccines/immunology
- Leishmaniasis, Visceral/immunology
- Leishmaniasis, Visceral/parasitology
- Leishmaniasis, Visceral/prevention & control
- Liver/metabolism
- Liver/parasitology
- Mice
- Mice, Inbred BALB C
- Spleen/metabolism
- Spleen/parasitology
Collapse
Affiliation(s)
- Doumet Georges Helou
- Université Paris-Saclay, CNRS, BioCis-UMR 8076, Châtenay-Malabry, France
- * E-mail: (DGH); (SC)
| | - Aurélie Mauras
- Université Paris-Saclay, CNRS, BioCis-UMR 8076, Châtenay-Malabry, France
| | | | | | | | | | - Sandrine Cojean
- Université Paris-Saclay, CNRS, BioCis-UMR 8076, Châtenay-Malabry, France
- * E-mail: (DGH); (SC)
| |
Collapse
|
16
|
Pomel S, Cojean S, Pons V, Cintrat JC, Nguyen L, Vacus J, Pruvost A, Barbier J, Gillet D, Loiseau PM. An adamantamine derivative as a drug candidate for the treatment of visceral leishmaniasis. J Antimicrob Chemother 2021; 76:2640-2650. [PMID: 34212184 DOI: 10.1093/jac/dkab226] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Accepted: 06/03/2021] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND This study aimed to investigate compounds acting on the host cell machinery to impair parasite installation with the possible advantage of limiting drug resistance. The strategy therefore consisted of selecting compounds that are poorly active on the axenic parasite, but very active on the intramacrophage form of Leishmania. OBJECTIVES To identify a drug candidate from focused screening of adamantamine derivatives that can inhibit the development of Leishmania infantum in macrophages. METHODS In vitro screening was performed on a library of 142 adamantamine derivatives with axenic and intramacrophage forms of L. infantum, as well as cytotoxicity assays, allowing selection of the most promising compound. Absorption, distribution, metabolism and excretion (ADME) experiments, including pharmacokinetics and microsomal stability, were performed and finally the physicochemical stability of the compound was investigated to assess its suitability for further drug development. RESULTS VP343 was identified first in vitro, with a CC50 value of 63.7 μM and an IC50 value of 0.32 μM for L. infantum intramacrophage amastigotes and then in vivo, with a 59% reduction of the liver parasite burden after oral administration at 10 mg/kg/day for 5 days. In addition, the ADME data were compatible with moving this compound further through the antileishmanial drug candidate pipeline. CONCLUSIONS VP343 has the properties of a good drug candidate and merits further investigations.
Collapse
Affiliation(s)
- Sébastien Pomel
- Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France
| | - Sandrine Cojean
- Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France
| | - Valérie Pons
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191, Gif-sur-Yvette, France
| | - Jean-Christophe Cintrat
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191, Gif-sur-Yvette, France
| | - Laetitia Nguyen
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 91191, Gif-sur-Yvette, France
| | - Joël Vacus
- Drugabilis, 7, Allée de Londres, 91140, Villejust, France
| | - Alain Pruvost
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 91191, Gif-sur-Yvette, France
| | - Julien Barbier
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191, Gif-sur-Yvette, France
| | - Daniel Gillet
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191, Gif-sur-Yvette, France
| | | |
Collapse
|
17
|
Pinet A, Cojean S, Nguyen LT, Vásquez-Ocmín P, Maciuk A, Loiseau PM, Le Pape P, Figadère B, Ferrié L. Anti-protozoal and anti-fungal evaluation of 3,5-disubstituted 1,2-dioxolanes. Bioorg Med Chem Lett 2021; 47:128196. [PMID: 34116159 DOI: 10.1016/j.bmcl.2021.128196] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 05/28/2021] [Accepted: 06/06/2021] [Indexed: 11/16/2022]
Abstract
Endoperoxides are a class of compounds, which is well-known for their antimalarial properties, but few reports exist about 3,5-disubstituted 1,2-dioxolanes. After having designed a new synthetic route for the preparation of these substances, they were evaluated against 4 different agents of infectious diseases, protozoa (Plasmodium and Leishmania) and Fungi (Candida and Aspergillus). Whereas moderate antifungal activity was found for our products, potent antimalarial and antileishmanial activities were observed for a few compounds. The nature of the substituents linked to the endoperoxide ring seems to play an important role in the bioactivities.
Collapse
Affiliation(s)
- Alexis Pinet
- BioCIS, CNRS, Université Paris-Saclay, Châtenay-Malabry 92290, France
| | - Sandrine Cojean
- BioCIS, CNRS, Université Paris-Saclay, Châtenay-Malabry 92290, France; National de Référence du Paludisme, Hôpital Bichat-Claude Bernard, APHP, 75018 Paris, France
| | - Linh Thuy Nguyen
- BioCIS, CNRS, Université Paris-Saclay, Châtenay-Malabry 92290, France; Institute of Marine Biochemistry (IMBC), Vietnam Academy of Science and Technology (VAST), Cau Giay, Hanoi, Viet Nam
| | | | - Alexandre Maciuk
- BioCIS, CNRS, Université Paris-Saclay, Châtenay-Malabry 92290, France
| | | | - Patrice Le Pape
- Department of Parasitology and Medical Mycology University of Nantes, EA1155 IICiMed, Nantes Atlantique Universities, Faculty of Pharmacy, Nantes, France
| | - Bruno Figadère
- BioCIS, CNRS, Université Paris-Saclay, Châtenay-Malabry 92290, France
| | - Laurent Ferrié
- BioCIS, CNRS, Université Paris-Saclay, Châtenay-Malabry 92290, France.
| |
Collapse
|
18
|
Taravaud A, Fechtali-Moute Z, Loiseau PM, Pomel S. Drugs used for the treatment of cerebral and disseminated infections caused by free-living amoebae. Clin Transl Sci 2021; 14:791-805. [PMID: 33650319 PMCID: PMC8212752 DOI: 10.1111/cts.12955] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2020] [Revised: 11/25/2020] [Accepted: 11/25/2020] [Indexed: 01/29/2023] Open
Abstract
Free‐living amoebae (FLAs) are protozoa developing autonomously in diverse natural or artificial environments. The FLAs Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria fowleri represent a risk for human health as they can become pathogenic and cause severe cerebral infections, named granulomatous amoebic encephalitis (GAE), Balamuthia amoebic encephalitis (BAE), and primary amoebic meningoencephalitis (PAM), respectively. Additionally, Acanthamoeba sp. can also rarely disseminate to diverse organs, such as the skin, sinuses, or bones, and cause extracerebral disseminated acanthamebiasis (EDA). No consensus treatment has been established for cerebral FLA infections or EDA. The therapy of cerebral and disseminated FLA infections often empirically associates a large diversity of drugs, all exhibiting a high toxicity. Nevertheless, these pathologies lead to a high mortality, above 90% of the cases, even in the presence of a treatment. In the present work, a total of 474 clinical cases of FLA infections gathered from the literature allowed to determine the frequency of usage, as well as the efficacy of the main drugs and drug combinations used in the treatment of these pathologies. The efficacy of drug usage was determined based on the survival rate after drug administration. The most efficient drugs, drug combinations, and their mechanism of action were discussed in regard to the present recommendations for the treatment of GAE, EDA, BAE, and PAM. At the end, this review aims to provide a useful tool for physicians in their choice to optimize the treatment of FLA infections.
Collapse
Affiliation(s)
- Alexandre Taravaud
- BioCIS, Université Paris-Sud, CNRS, Université Paris-Saclay, Châtenay-Malabry, France
| | - Zineb Fechtali-Moute
- BioCIS, Université Paris-Sud, CNRS, Université Paris-Saclay, Châtenay-Malabry, France
| | - Philippe M Loiseau
- BioCIS, Université Paris-Sud, CNRS, Université Paris-Saclay, Châtenay-Malabry, France
| | - Sébastien Pomel
- BioCIS, Université Paris-Sud, CNRS, Université Paris-Saclay, Châtenay-Malabry, France
| |
Collapse
|
19
|
Maaroufi Z, Cojean S, Loiseau PM, Yahyaoui M, Agnely F, Abderraba M, Mekhloufi G. In vitro antileishmanial potentialities of essential oils from Citrus limon and Pistacia lentiscus harvested in Tunisia. Parasitol Res 2021; 120:1455-1469. [PMID: 33426571 DOI: 10.1007/s00436-020-06952-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Accepted: 10/28/2020] [Indexed: 10/22/2022]
Abstract
Leishmaniasis is a tropical parasitic disease that affects up to 12 million people worldwide. Current chemotherapies have limitations such as toxicity, high cost, and parasite resistance. This work aims to select an essential oil (EssOil) isolated from the Tunisian flora as a new antileishmanial candidate. Two plants were chosen for their antileishmanial potential: Citrus limon (Citrus) and Pistacia lentiscus (Pistacia). Each of these plants was harvested from two different sites (area 1 and area 2). Extracted EssOils were characterized using GC-MS. Their antiparasitic activity against axenic and intracellular Leishmania major amastigotes and their cytotoxicity were assessed. Citrus EssOil from area 1 displayed an interesting activity against L. major intramacrophage amastigotes with IC50 value at 4.2 ± 1.3 μg/mL. Interestingly, this activity was close to that of miltefosine. Moderate activities against intracellular amastigote were observed for Pistacia EssOil from area 1 and Citrus EssOil from area 2. However, low cytotoxicity with high selectivity index was proved only for Citrus EssOil from area 1, revealing its safety for macrophages. This study also demonstrated for the first time the antileishmanial activity of EssOil extracted from Citrus limon leaves. The EssOil interesting activity could be related to the lipophilic properties of terpenes that were shown in literature to contribute to the disruption of parasite intracellular metabolic pathways.
Collapse
Affiliation(s)
- Zeineb Maaroufi
- CNRS, Institut Galien Paris-Saclay, Université Paris-Saclay, 92296, Châtenay-Malabry, France.,Laboratoire Matériaux Molécules et applications, Institut préparatoire des études scientifiques et techniques (IPEST), Univ. de Carthage, La Marsa, Tunisia
| | - Sandrine Cojean
- CNRS, BioCIS, Université Paris-Saclay, 92290, Châtenay-Malabry, France
| | | | - Marwa Yahyaoui
- Laboratoire Matériaux Molécules et applications, Institut préparatoire des études scientifiques et techniques (IPEST), Univ. de Carthage, La Marsa, Tunisia
| | - Florence Agnely
- CNRS, Institut Galien Paris-Saclay, Université Paris-Saclay, 92296, Châtenay-Malabry, France
| | - Manef Abderraba
- Laboratoire Matériaux Molécules et applications, Institut préparatoire des études scientifiques et techniques (IPEST), Univ. de Carthage, La Marsa, Tunisia
| | - Ghozlene Mekhloufi
- CNRS, Institut Galien Paris-Saclay, Université Paris-Saclay, 92296, Châtenay-Malabry, France.
| |
Collapse
|
20
|
Feng L, Pomel S, Latre de Late P, Taravaud A, Loiseau PM, Maes L, Cho-Ngwa F, Bulman CA, Fischer C, Sakanari JA, Ziniel PD, Williams DL, Davioud-Charvet E. Repurposing Auranofin and Evaluation of a New Gold(I) Compound for the Search of Treatment of Human and Cattle Parasitic Diseases: From Protozoa to Helminth Infections. Molecules 2020; 25:molecules25215075. [PMID: 33139647 PMCID: PMC7663263 DOI: 10.3390/molecules25215075] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Revised: 10/25/2020] [Accepted: 10/27/2020] [Indexed: 12/12/2022] Open
Abstract
Neglected parasitic diseases remain a major public health issue worldwide, especially in tropical and subtropical areas. Human parasite diversity is very large, ranging from protozoa to worms. In most cases, more effective and new drugs are urgently needed. Previous studies indicated that the gold(I) drug auranofin (Ridaura®) is effective against several parasites. Among new gold(I) complexes, the phosphole-containing gold(I) complex {1-phenyl-2,5-di(2-pyridyl)phosphole}AuCl (abbreviated as GoPI) is an irreversible inhibitor of both purified human glutathione and thioredoxin reductases. GoPI-sugar is a novel 1-thio-β-d-glucopyranose 2,3,4,6-tetraacetato-S-derivative that is a chimera of the structures of GoPI and auranofin, designed to improve stability and bioavailability of GoPI. These metal-ligand complexes are of particular interest because of their combined abilities to irreversibly target the essential dithiol/selenol catalytic pair of selenium-dependent thioredoxin reductase activity, and to kill cells from breast and brain tumors. In this work, screening of various parasites—protozoans, trematodes, and nematodes—was undertaken to determine the in vitro killing activity of GoPI-sugar compared to auranofin. GoPI-sugar was found to efficiently kill intramacrophagic Leishmania donovani amastigotes and adult filarial and trematode worms.
Collapse
Affiliation(s)
- Liwen Feng
- UMR 7042 CNRS-Université de Strasbourg-Université Haute-Alsace, Laboratoire d’Innovation Moléculaire et Applications (LIMA), Bioorganic and Medicinal Chemistry Team, European School of Chemistry, Polymers and Materials (ECPM), 25, rue Becquerel, F-67087 Strasbourg, France;
| | - Sébastien Pomel
- BioCIS, Faculty of Pharmacy, Université Paris-Saclay, CNRS, 92290 Châtenay-Malabry, France; (S.P.); (A.T.); (P.M.L.)
| | - Perle Latre de Late
- INSERM U1016, CNRS UMR 8104, Laboratoire de Biologie Cellulaire Comparative des Apicomplexes, Cochin Institute, Faculté de Medecine, Université Paris Descartes, Sorbonne Paris Cité, 75014 Paris, France;
| | - Alexandre Taravaud
- BioCIS, Faculty of Pharmacy, Université Paris-Saclay, CNRS, 92290 Châtenay-Malabry, France; (S.P.); (A.T.); (P.M.L.)
| | - Philippe M. Loiseau
- BioCIS, Faculty of Pharmacy, Université Paris-Saclay, CNRS, 92290 Châtenay-Malabry, France; (S.P.); (A.T.); (P.M.L.)
| | - Louis Maes
- Laboratory of Microbiology, Parasitology and Hygiene (LMPH), Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium;
| | - Fidelis Cho-Ngwa
- Biotechnology Unit, Faculty of Science, University of Buea, Buea P.O. Box 63, Cameroon;
| | - Christina A. Bulman
- Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA; (C.A.B.); (C.F.); (J.A.S.)
| | - Chelsea Fischer
- Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA; (C.A.B.); (C.F.); (J.A.S.)
| | - Judy A. Sakanari
- Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA; (C.A.B.); (C.F.); (J.A.S.)
| | - Peter D. Ziniel
- Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, IL 60612, USA;
| | - David L. Williams
- Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, IL 60612, USA;
- Correspondence: (D.L.W.); (E.D.-C.)
| | - Elisabeth Davioud-Charvet
- UMR 7042 CNRS-Université de Strasbourg-Université Haute-Alsace, Laboratoire d’Innovation Moléculaire et Applications (LIMA), Bioorganic and Medicinal Chemistry Team, European School of Chemistry, Polymers and Materials (ECPM), 25, rue Becquerel, F-67087 Strasbourg, France;
- Correspondence: (D.L.W.); (E.D.-C.)
| |
Collapse
|
21
|
Bazin MA, Cojean S, Pagniez F, Bernadat G, Cavé C, Ourliac-Garnier I, Nourrisson MR, Morgado C, Picot C, Leclercq O, Baratte B, Robert T, Späth GF, Rachidi N, Bach S, Loiseau PM, Le Pape P, Marchand P. In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition. Eur J Med Chem 2020; 210:112956. [PMID: 33148491 DOI: 10.1016/j.ejmech.2020.112956] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2020] [Revised: 10/19/2020] [Accepted: 10/19/2020] [Indexed: 12/15/2022]
Abstract
Leishmaniasis constitutes a severe public health problem, with an estimated prevalence of 12 million cases. This potentially fatal disease has a worldwide distribution and in 2012, the fatal Visceral Leishmaniasis (VL) was declared as new emerging disease in Europe, mainly due to global warming, with expected important public health impact. The available treatments are toxic, costly or lead to parasite resistance, thus there is an urgent need for new drugs with new mechanism of action. Previously, we reported the discovery of CTN1122, a potent imidazo[1,2-a]pyrazine-based antileishmanial hit compound targeting L-CK1.2 at low micromolar ranges. Here, we described structurally related, safe and selective compounds endowed with antiparasitic properties, better than miltefosine, the reference therapy by oral route. L-CK1.2 homology model gave the first structural explanations of the role of 4-pyridyl (CTN1122) and 2-aminopyrimidin-4-yl (compound 21) moieties, at the position 3 of the central core, in the low micromolar to nanomolar L-CK1.2 inhibition, whereas N-methylpyrazole derivative 11 remained inactive against the parasite kinase.
Collapse
Affiliation(s)
- Marc-Antoine Bazin
- Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000, Nantes, France
| | - Sandrine Cojean
- BioCIS Biomolécules: Conception, Isolement, Synthèse, Chimiothérapie Antiparasitaire, UMR CNRS 8076, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, F-92296, Châtenay-Malabry, France
| | - Fabrice Pagniez
- Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000, Nantes, France
| | - Guillaume Bernadat
- BioCIS Biomolécules: Conception, Isolement, Synthèse, Chimiothérapie Antiparasitaire, UMR CNRS 8076, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, F-92296, Châtenay-Malabry, France
| | - Christian Cavé
- BioCIS Biomolécules: Conception, Isolement, Synthèse, Chimiothérapie Antiparasitaire, UMR CNRS 8076, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, F-92296, Châtenay-Malabry, France
| | - Isabelle Ourliac-Garnier
- Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000, Nantes, France
| | - Marie-Renée Nourrisson
- Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000, Nantes, France
| | - Cathy Morgado
- Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000, Nantes, France
| | - Carine Picot
- Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000, Nantes, France
| | - Olivier Leclercq
- Institut Pasteur and Institut National de Santé et Recherche Médicale INSERM U1201, Unité de Parasitologie Moléculaire et Signalisation, F-75015, Paris, France
| | - Blandine Baratte
- Sorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, F-29680, Roscoff, France; Sorbonne Université, CNRS, FR2424, Kinase Inhibitor Specialized Screening Facility - KISSf, Station Biologique, F-29680, Roscoff, France
| | - Thomas Robert
- Sorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, F-29680, Roscoff, France; Sorbonne Université, CNRS, FR2424, Kinase Inhibitor Specialized Screening Facility - KISSf, Station Biologique, F-29680, Roscoff, France
| | - Gérald F Späth
- Institut Pasteur and Institut National de Santé et Recherche Médicale INSERM U1201, Unité de Parasitologie Moléculaire et Signalisation, F-75015, Paris, France
| | - Najma Rachidi
- Institut Pasteur and Institut National de Santé et Recherche Médicale INSERM U1201, Unité de Parasitologie Moléculaire et Signalisation, F-75015, Paris, France
| | - Stéphane Bach
- Sorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, F-29680, Roscoff, France; Sorbonne Université, CNRS, FR2424, Kinase Inhibitor Specialized Screening Facility - KISSf, Station Biologique, F-29680, Roscoff, France
| | - Philippe M Loiseau
- BioCIS Biomolécules: Conception, Isolement, Synthèse, Chimiothérapie Antiparasitaire, UMR CNRS 8076, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, F-92296, Châtenay-Malabry, France
| | - Patrice Le Pape
- Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000, Nantes, France
| | - Pascal Marchand
- Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000, Nantes, France.
| |
Collapse
|
22
|
Loiseau PM, Pomel S, Croft SL. Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis. Molecules 2020; 25:E4123. [PMID: 32916994 PMCID: PMC7571104 DOI: 10.3390/molecules25184123] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Revised: 09/07/2020] [Accepted: 09/08/2020] [Indexed: 12/11/2022] Open
Abstract
The control of leishmaniases, a complex parasitic disease caused by the protozoan parasite Leishmania, requires continuous innovation at the therapeutic and vaccination levels. Chitosan is a biocompatible polymer administrable via different routes and possessing numerous qualities to be used in the antileishmanial strategies. This review presents recent progress in chitosan research for antileishmanial applications. First data on the mechanism of action of chitosan revealed an optimal in vitro intrinsic activity at acidic pH, high-molecular-weight chitosan being the most efficient form, with an uptake by pinocytosis and an accumulation in the parasitophorous vacuole of Leishmania-infected macrophages. In addition, the immunomodulatory effect of chitosan is an added value both for the treatment of leishmaniasis and the development of innovative vaccines. The advances in chitosan chemistry allows pharmacomodulation on amine groups opening various opportunities for new polymers of different size, and physico-chemical properties adapted to the chosen routes of administration. Different formulations have been studied in experimental leishmaniasis models to cure visceral and cutaneous leishmaniasis, and chitosan can act as a booster through drug combinations with classical drugs, such as amphotericin B. The various architectural possibilities given by chitosan chemistry and pharmaceutical technology pave the way for promising further developments.
Collapse
Affiliation(s)
- Philippe M. Loiseau
- Antiparasite Chemotherapy, CNRS, BioCIS, Université Paris-Saclay, 92290 Châtenay-Malabry, France;
| | - Sébastien Pomel
- Antiparasite Chemotherapy, CNRS, BioCIS, Université Paris-Saclay, 92290 Châtenay-Malabry, France;
| | - Simon L. Croft
- Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK;
| |
Collapse
|
23
|
Goyal S, Binnington B, McCarthy SDS, Desmaële D, Férrié L, Figadère B, Loiseau PM, Branch DR. Inhibition of in vitro Ebola infection by anti-parasitic quinoline derivatives. F1000Res 2020; 9:268. [PMID: 32528661 PMCID: PMC7268155 DOI: 10.12688/f1000research.22352.1] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/06/2020] [Indexed: 11/20/2022] Open
Abstract
There continues to be no approved drugs for the treatment of Ebola virus disease (EVD). Despite a number of candidate drugs showing limited efficacy
in vitro and/or in non-human primate studies, EVD continues to plaque certain areas of Africa without any efficacious treatments yet available. Recently, we have been exploring the potential for anti-malarial drugs to inhibit an
in vitro model of Ebola Zaire replication using a transcription-competent virus-like particle (trVLP) assay. We examined the efficacy of chloroquine, amodiaquine and 36 novel anti-parasite quinoline derivatives at inhibiting Ebola virus replication. Drug efficacy was tested by trVLP assay and toxicity by MTT assay. Both chloroquine and amodiaquine were effective for inhibition of Ebola virus replication without significant toxicity. The half-maximal inhibitory concentration (IC
50) of chloroquine and amodiaquine to inhibit Ebola virus replication were IC
50, Chl = 3.95 µM and IC
50, Amo = 1.45 µM, respectively. Additionally, three novel quinoline derivatives were identified as having inhibitory activity and low toxicity for Ebola trVLP replication, with 2NH2Q being the most promising derivative, with an IC
50 of 4.66 µM. Quinoline compounds offer many advantages for disease treatment in tropical climates as they are cheap to produce, easy to synthesize and chemically stable. In this report, we have demonstrated the potential of anti-parasite quinolines for further investigation for use in EVD.
Collapse
Affiliation(s)
- Shawn Goyal
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, M5H 2N2, Canada
| | - Beth Binnington
- Centre for Innovation, Canadian Blood Services, Toronto, Ontario, M5H 2N2, Canada
| | - Stephen D S McCarthy
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, M5H 2N2, Canada
| | - Didier Desmaële
- Institut Galien, CNRS, Université Paris-Saclay, 5 Rue Jean-Baptiste Clément, Chatenay-Malabry, 92290, France
| | - Laurent Férrié
- CNRS BioCIS, Université Paris-Saclay, Châtenay-Malabry, 92290, France
| | - Bruno Figadère
- CNRS BioCIS, Université Paris-Saclay, Châtenay-Malabry, 92290, France
| | | | - Donald R Branch
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, M5H 2N2, Canada.,Centre for Innovation, Canadian Blood Services, Toronto, Ontario, M5H 2N2, Canada.,Department of Medicine, University of Toronto, Toronto, Ontario, Canada.,Division of Advanced Diagnostics, Toronto General Hospital Research Institute, Toronto, Ontario, Canada
| |
Collapse
|
24
|
Lanza JS, Vucen S, Flynn O, Donadei A, Cojean S, Loiseau PM, Fernandes APSM, Frézard F, Moore AC. A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization. Int J Pharm 2020; 586:119390. [PMID: 32540349 DOI: 10.1016/j.ijpharm.2020.119390] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Revised: 04/11/2020] [Accepted: 04/28/2020] [Indexed: 12/13/2022]
Abstract
Re-emergence and geographic expansion of leishmaniasis is accelerating efforts to develop a safe and effective Leshmania vaccine. Vaccines using Leishmania recombinant antigens, such as LiHyp1, which is mostly present in the amastigote parasite form, are being developed as a next generation to crude killed parasite-based vaccines. The main objective of this work was to develop a LiHyp1-based vaccine and determine if it can induce protective immunity in BALB/c mice when administered using a dissolvable microneedle (DMN) patch by the skin route. The LiHyp1 antigen was incorporated into cationic liposomes (CL), with or without the TLR9 agonist, CpG. The LiHyp1-liposomal vaccines were characterized with respect to size, protein encapsulation rates and retention of their physical characteristics after incorporation into the DMN patch. DMN mechanical strength and skin penetration ability were tested. A vaccine composed of LiHyp1, CpG and liposomes and subcutaneously injected or a vaccine containing antigen and CpG in DMN patches, without liposomes, induced high antibody responses and significant levels of protection against L. donovani parasite infection. This study progresses the development of an efficacious leishmania vaccine by detailing promising vaccine formulations and skin delivery technologies and it addresses protective efficacy of a liposome-based dissolvable microneedle patch vaccine system.
Collapse
Affiliation(s)
- Juliane S Lanza
- Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Antiparasite Chemotherapy, UMR 8076 CNRS BioCIS, Faculté de Pharmacie, Université Paris-Sud, Université Paris-Saclay, Chatenay-Malabry, France
| | - Sonja Vucen
- School of Pharmacy, University College Cork, Cork, Ireland
| | - Olivia Flynn
- School of Pharmacy, University College Cork, Cork, Ireland
| | - Agnese Donadei
- School of Pharmacy, University College Cork, Cork, Ireland
| | - Sandrine Cojean
- Antiparasite Chemotherapy, UMR 8076 CNRS BioCIS, Faculté de Pharmacie, Université Paris-Sud, Université Paris-Saclay, Chatenay-Malabry, France
| | - Philippe M Loiseau
- Antiparasite Chemotherapy, UMR 8076 CNRS BioCIS, Faculté de Pharmacie, Université Paris-Sud, Université Paris-Saclay, Chatenay-Malabry, France
| | - Ana Paula S M Fernandes
- Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Frédéric Frézard
- Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Anne C Moore
- School of Pharmacy, University College Cork, Cork, Ireland; School of Biochemistry and Cell Biology, University College Cork, Cork, Ireland.
| |
Collapse
|
25
|
Abstract
Trichomonas vaginalis motility in biological fluids plays a prominent, but understudied, role in parasite infectivity. In this study, the ability of a thermosensitive hydrogel (pluronic F127) to physically immobilize T. vaginalis was investigated. Blocking parasite motility could prevent its attachment to the mucosa, thus reducing the acquisition of the infection. The trajectory of individual parasites was monitored by multiple particle tracking. Mean square displacement, diffusivity, and velocity were calculated from x, y coordinates during time. Major results are that T. vaginalis exhibited different types of trajectories in a diluted solution composed of lactate buffer similar to "run-and-tumble" motion reported for flagellated bacteria. The fastest T. vaginalis specimen moves with a velocity of 19 μm/s. Observation of T. vaginalis movements showed that the cell body remains rigid during swimming and that the propulsive forces necessary to generate the movement are the result of flagellar beating. Parasite motility was partially slowed down using hydroxyethylcellulose hydrogel, used as a reference for the development of vaginal microbicides, while 100% of T. vaginalis were immobile in F127 hydrogel. Once completed by biological investigations on mice, this report suggests using drug-free formulation composed of F127 as a new strategy to prevent T. vaginalis attachment to the mucosa. The concept will be extended to other flagellated organisms where the motility is driven by cilia and flagella.
Collapse
Affiliation(s)
- Sophia Malli
- Institut Galien Paris Sud, UMR CNRS 8612, Université Paris-Sud, Faculté de Pharmacie, Université Paris-Saclay, 5, rue J-B. Clément, 92296, Châtenay-Malabry, France
- Institut Galien Paris Sud, Junior member of the Institut Universitaire de France, UMR CNRS 8612, Université Paris-Sud, Faculté de Pharmacie, Université Paris-Saclay, 5, rue J-B. Clément, 92296 Châtenay-Malabry, France
| | - Philippe M. Loiseau
- Antiparasite Chemotherapy PARACHEM, Université Paris-Sud, CNRS, 5, rue J-B. Clément, 92290 Châtenay-Malabry, France
| | - Kawthar Bouchemal
- Institut Galien Paris Sud, Junior member of the Institut Universitaire de France, UMR CNRS 8612, Université Paris-Sud, Faculté de Pharmacie, Université Paris-Saclay, 5, rue J-B. Clément, 92296 Châtenay-Malabry, France
| |
Collapse
|
26
|
Lanza JS, Pomel S, Loiseau PM, Frézard F. Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases. Expert Opin Drug Deliv 2019; 16:1063-1079. [DOI: 10.1080/17425247.2019.1659243] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Juliane S. Lanza
- Faculty of Pharmacy, Antiparasite Chemotherapy, UMR 8076 CNRS BioCIS, University Paris-Saclay, Chatenay-Malabry, France
| | - Sébastien Pomel
- Faculty of Pharmacy, Antiparasite Chemotherapy, UMR 8076 CNRS BioCIS, University Paris-Saclay, Chatenay-Malabry, France
| | - Philippe M. Loiseau
- Faculty of Pharmacy, Antiparasite Chemotherapy, UMR 8076 CNRS BioCIS, University Paris-Saclay, Chatenay-Malabry, France
| | - Frédéric Frézard
- Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil
| |
Collapse
|
27
|
Pomel S, Mao W, Ha-Duong T, Cavé C, Loiseau PM. GDP-Mannose Pyrophosphorylase: A Biologically Validated Target for Drug Development Against Leishmaniasis. Front Cell Infect Microbiol 2019; 9:186. [PMID: 31214516 PMCID: PMC6554559 DOI: 10.3389/fcimb.2019.00186] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Accepted: 05/15/2019] [Indexed: 01/02/2023] Open
Abstract
Leishmaniases are neglected tropical diseases that threaten about 350 million people in 98 countries around the world. In order to find new antileishmanial drugs, an original approach consists in reducing the pathogenic effect of the parasite by impairing the glycoconjugate biosynthesis, necessary for parasite recognition and internalization by the macrophage. Some proteins appear to be critical in this way, and one of them, the GDP-Mannose Pyrophosphorylase (GDP-MP), is an attractive target for the design of specific inhibitors as it is essential for Leishmania survival and it presents significant differences with the host counterpart. Two GDP-MP inhibitors, compounds A and B, have been identified in two distinct studies by high throughput screening and by a rational approach based on molecular modeling, respectively. Compound B was found to be the most promising as it exhibited specific competitive inhibition of leishmanial GDP-MP and antileishmanial activities at the micromolar range with interesting selectivity indexes, as opposed to compound A. Therefore, compound B can be used as a pharmacological tool for the development of new specific antileishmanial drugs.
Collapse
Affiliation(s)
- Sébastien Pomel
- UMR 8076 CNRS BioCIS, Université Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France
| | - Wei Mao
- UMR 8076 CNRS BioCIS, Université Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France
| | - Tâp Ha-Duong
- UMR 8076 CNRS BioCIS, Université Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France
| | - Christian Cavé
- UMR 8076 CNRS BioCIS, Université Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France
| | - Philippe M Loiseau
- UMR 8076 CNRS BioCIS, Université Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France
| |
Collapse
|
28
|
Malli S, Pomel S, Ayadi Y, Deloménie C, Da Costa A, Loiseau PM, Bouchemal K. Topically Applied Chitosan-Coated Poly(isobutylcyanoacrylate) Nanoparticles Are Active Against Cutaneous Leishmaniasis by Accelerating Lesion Healing and Reducing the Parasitic Load. ACS Appl Bio Mater 2019; 2:2573-2586. [DOI: 10.1021/acsabm.9b00263] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- Sophia Malli
- Institut Galien Paris Sud, UMR CNRS 8612, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5, rue J.B. Clément, 92296 Cedex Châtenay-Malabry, France
- BioCIS Biomolécules: Conception, Isolement, Synthèse, Chimiothérapie Antiparasitaire, UMR CNRS 8076, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5, rue J.B. Clément, 92296 Cedex Châtenay-Malabry, France
| | - Sebastien Pomel
- BioCIS Biomolécules: Conception, Isolement, Synthèse, Chimiothérapie Antiparasitaire, UMR CNRS 8076, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5, rue J.B. Clément, 92296 Cedex Châtenay-Malabry, France
| | - Yasmine Ayadi
- Institut Galien Paris Sud, UMR CNRS 8612, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5, rue J.B. Clément, 92296 Cedex Châtenay-Malabry, France
- BioCIS Biomolécules: Conception, Isolement, Synthèse, Chimiothérapie Antiparasitaire, UMR CNRS 8076, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5, rue J.B. Clément, 92296 Cedex Châtenay-Malabry, France
| | - Claudine Deloménie
- Faculté de Pharmacie, Institut Paris Saclay d’Innovation Thérapeutique, UMS Inserm CNRS UPSud, Université Paris-Saclay, 92296 Cedex Châtenay-Malabry, France
| | - Antonio Da Costa
- Université d’Artois, CNRS, Centrale Lille, ENSCL, Université Lille, UMR 8181, Unité de Catalyse et de Chimie du Solide (UCCS), Faculté Jean-Perrin, Rue Jean Souvras − SP 18, 62307 Lens, France
| | - Philippe M. Loiseau
- BioCIS Biomolécules: Conception, Isolement, Synthèse, Chimiothérapie Antiparasitaire, UMR CNRS 8076, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5, rue J.B. Clément, 92296 Cedex Châtenay-Malabry, France
| | - Kawthar Bouchemal
- Institut Galien Paris Sud, Junior Member of the Institut Universitaire de France, UMR CNRS 8612, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5, rue J.B. Clément, 92296 Cedex Châtenay-Malabry, France
| |
Collapse
|
29
|
Stevanovic S, Sencanski M, Danel M, Menendez C, Belguedj R, Bouraiou A, Nikolic K, Cojean S, Loiseau PM, Glisic S, Baltas M, García-Sosa AT. Synthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets. Molecules 2019; 24:molecules24071282. [PMID: 30986947 PMCID: PMC6480966 DOI: 10.3390/molecules24071282] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 03/20/2019] [Accepted: 03/28/2019] [Indexed: 11/24/2022] Open
Abstract
Due to the lack of approved vaccines against human leishmaniasis and the limitations of the current chemotherapy inducing side effects and drug resistance, development of new, effective chemotherapeutic agents is essential. This study describes the synthesis of a series of novel oxadiazoles and indolizine-containing compounds. The compounds were screened in silico using an EIIP/AQVN filter followed by ligand-based virtual screening and molecular docking to parasite arginase. Top hits were further screened versus human arginase and finally against an anti-target battery to tag their possible interactions with proteins essential for the metabolism and clearance of many substances. Eight candidate compounds were selected for further experimental testing. The results show measurable in vitro anti-leishmanial activity for three compounds. One compound with an IC50 value of 2.18 µM on Leishmania donovani intramacrophage amastigotes is clearly better positioned than the others as an interesting molecular template for further development of new anti-leishmanial agents.
Collapse
Affiliation(s)
- Strahinja Stevanovic
- Laboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences VINCA, University of Belgrade, P.O. Box 522, 11001 Belgrade, Serbia.
| | - Milan Sencanski
- Laboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences VINCA, University of Belgrade, P.O. Box 522, 11001 Belgrade, Serbia.
| | - Mathieu Danel
- ITAV, Université de Toulouse, CNRS, 31062 Toulouse, France.
| | - Christophe Menendez
- Department of Chemistry, Université de Toulouse, UPS, CNRS UMR 5068, LSPCMIB, 118 Route de Narbonne, 31062 Toulouse, France.
- CNRS, Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique, LSPCMIB, UMR-5068, 118 Route de Narbonne, 31062 Toulouse, France.
| | - Roumaissa Belguedj
- Department of Chemistry, Université de Toulouse, UPS, CNRS UMR 5068, LSPCMIB, 118 Route de Narbonne, 31062 Toulouse, France.
- CNRS, Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique, LSPCMIB, UMR-5068, 118 Route de Narbonne, 31062 Toulouse, France.
- Unité de Recherche de Chimie de l'Environnement et Moléculaire Structurale, Université Frères Mentouri, Route de Ain El Bey, 25000 Constantine, Algeria.
| | - Abdelmalek Bouraiou
- Unité de Recherche de Chimie de l'Environnement et Moléculaire Structurale, Université Frères Mentouri, Route de Ain El Bey, 25000 Constantine, Algeria.
| | - Katarina Nikolic
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia.
| | - Sandrine Cojean
- Antiparasitic Chemotherapy, UMR 8076 CNRS BioCIS, Faculty of Pharmacy Université Paris-Sud, Rue Jean-Baptiste Clément, F 92290 Chatenay-Malabry, France.
| | - Philippe M Loiseau
- Antiparasitic Chemotherapy, UMR 8076 CNRS BioCIS, Faculty of Pharmacy Université Paris-Sud, Rue Jean-Baptiste Clément, F 92290 Chatenay-Malabry, France.
| | - Sanja Glisic
- Laboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences VINCA, University of Belgrade, P.O. Box 522, 11001 Belgrade, Serbia.
| | - Michel Baltas
- Department of Chemistry, Université de Toulouse, UPS, CNRS UMR 5068, LSPCMIB, 118 Route de Narbonne, 31062 Toulouse, France.
- CNRS, Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique, LSPCMIB, UMR-5068, 118 Route de Narbonne, 31062 Toulouse, France.
| | | |
Collapse
|
30
|
Malli S, Pomel S, Dennemont I, Loiseau PM, Bouchemal K. Combination of amphotericin B and chitosan platelets for the treatment of experimental cutaneous leishmaniasis: Histological and immunohistochemical examinations. J Drug Deliv Sci Technol 2019. [DOI: 10.1016/j.jddst.2018.12.031] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
31
|
El Ghozlani M, Bouissane L, Berkani M, Mojahidi S, Allam A, Menendez C, Cojean S, Loiseau PM, Baltas M, Rakib EM. Synthesis and biological evaluation against Leishmania donovani of novel hybrid molecules containing indazole-based 2-pyrone scaffolds. Medchemcomm 2018; 10:120-127. [PMID: 30774860 DOI: 10.1039/c8md00475g] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Accepted: 11/15/2018] [Indexed: 11/21/2022]
Abstract
A series of novel indazole-pyrone hybrids were synthesized by a one pot reaction between N-alkyl-6(5)-nitroindazoles and 2-pyrone (4-hydroxy-6-methyl-2H-pyran-2-one) using indium or stannous chloride as the reducing system in the presence of acetic acid in tetrahydrofuran. The hybrid molecules were obtained in good to excellent yields (72-92%) and characterized by NMR and single crystal X-ray diffraction. Nineteen compounds were tested in vitro against both Leishmania donovani (MHOM/ET/67/HU3, also called LV9) axenic and intramacrophage amastigotes. Among all, five compounds showed anti-leishmanial activity against intracellular L. donovani with an IC50 in the range of 2.25 to 62.56 μM. 3-(1-(3-Chloro-2-ethyl-2H-indazol-6-ylamino)ethylidene)-6-methyl-3H-pyran-2,4-dione 6f was found to be the most active compound for axenic amastigotes and intramacrophage amastigotes of L. donovani with IC50 values of 2.48 ± 1.02 μM and 2.25 ± 1.89 μM, respectively. However, the cytotoxicity of the most promising compound justifies further pharmacomodulations.
Collapse
Affiliation(s)
- M El Ghozlani
- Laboratoire de Chimie Organique et Analytiques , Faculté des Sciences et Techniques , Université Sultan Moulay Slimane , B.P. 523, Béni-Mellal , Morocco .
| | - L Bouissane
- Laboratoire de Chimie Organique et Analytiques , Faculté des Sciences et Techniques , Université Sultan Moulay Slimane , B.P. 523, Béni-Mellal , Morocco .
| | - M Berkani
- Laboratoire de Chimie Organique et Analytiques , Faculté des Sciences et Techniques , Université Sultan Moulay Slimane , B.P. 523, Béni-Mellal , Morocco .
| | - S Mojahidi
- Laboratoire de Chimie Organique et Analytiques , Faculté des Sciences et Techniques , Université Sultan Moulay Slimane , B.P. 523, Béni-Mellal , Morocco .
| | - A Allam
- Laboratoire de Chimie Organique et Analytiques , Faculté des Sciences et Techniques , Université Sultan Moulay Slimane , B.P. 523, Béni-Mellal , Morocco .
| | - C Menendez
- Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique , Université Paul Sabatier , UMR-CNRS 5068, 118 route de Narbonne , 31062 Toulouse cedex 9 , France
| | - S Cojean
- Chimiothérapie Antiparasitaire , UMR 8076 CNRS Faculté de Pharmacie , Université Paris-Saclay , Rue Jean-Baptiste Clément , F-92290 Chatenay-Malabry , France
| | - P M Loiseau
- Chimiothérapie Antiparasitaire , UMR 8076 CNRS Faculté de Pharmacie , Université Paris-Saclay , Rue Jean-Baptiste Clément , F-92290 Chatenay-Malabry , France
| | - M Baltas
- Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique , Université Paul Sabatier , UMR-CNRS 5068, 118 route de Narbonne , 31062 Toulouse cedex 9 , France
| | - E M Rakib
- Laboratoire de Chimie Organique et Analytiques , Faculté des Sciences et Techniques , Université Sultan Moulay Slimane , B.P. 523, Béni-Mellal , Morocco .
| |
Collapse
|
32
|
Taravaud A, Ali M, Lafosse B, Nicolas V, Féliers C, Thibert S, Lévi Y, Loiseau PM, Pomel S. Enrichment of free-living amoebae in biofilms developed at upper water levels in drinking water storage towers: An inter- and intra-seasonal study. Sci Total Environ 2018; 633:157-166. [PMID: 29573682 DOI: 10.1016/j.scitotenv.2018.03.178] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Revised: 03/16/2018] [Accepted: 03/16/2018] [Indexed: 06/08/2023]
Abstract
Free-living amoebae (FLA) are ubiquitous organisms present in various natural and artificial environments, such as drinking water storage towers (DWST). Some FLA, such as Acanthamoeba sp., Naegleria fowleri, and Balamuthia mandrillaris, can cause severe infections at ocular or cerebral level in addition to being potential reservoirs of other pathogens. In this work, the abundance and diversity of FLA was evaluated in two sampling campaigns: one performed over five seasons in three DWST at three different levels (surface, middle and bottom) in water and biofilm using microscopy and PCR, and one based on the kinetics analysis in phase contrast and confocal microscopy of biofilm samples collected every two weeks during a 3-month period at the surface and at the bottom of a DWST. In the seasonal study, the FLA were detected in each DWST water in densities of ~20 to 25amoebaeL-1. A seasonal variation of amoeba distribution was observed in water samples, with maximal densities in summer at ~30amoebaeL-1 and minimal densities in winter at ~16amoebaeL-1. The FLA belonging to the genus Acanthamoeba were detected in two spring sampling campaigns, suggesting a possible seasonal appearance of this potentially pathogenic amoeba. Interestingly, a 1 log increase of amoebae density was observed in biofilm samples collected at the surface of all DWST compared to the middle and the bottom where FLA were at 0.1-0.2amoebae/cm2. In the kinetics study, an increase of amoebae density, total cell density, and biofilm thickness was observed as a function of time at the surface of the DWST, but not at the bottom. To our knowledge, this study describes for the first time a marked higher FLA density in biofilms collected at upper water levels in DWST, constituting a potential source of pathogenic micro-organisms.
Collapse
Affiliation(s)
- Alexandre Taravaud
- Chimiothérapie Antiparasitaire, UMR CNRS 8076, BioCIS, Université Paris-Sud, Université Paris-Saclay, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France
| | - Myriam Ali
- Chimiothérapie Antiparasitaire, UMR CNRS 8076, BioCIS, Université Paris-Sud, Université Paris-Saclay, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France
| | - Bernard Lafosse
- Véolia Eau-Compagnie Générale des Eaux, 2 avenue Guynemer, 94600 Choisy-Le-Roi, France
| | - Valérie Nicolas
- UMS IPSIT, Plate-Forme D'imagerie Cellulaire, Université Paris-Sud, Université Paris-Saclay, 92290 Châtenay-Malabry, France
| | - Cédric Féliers
- Véolia Eau d'Île de France, Le Vermont, 28 boulevard de Pesaro, 92751 Nanterre, France
| | - Sylvie Thibert
- Syndicat des Eaux d'Île de France, 120 boulevard Saint-Germain, 75006 Paris, France
| | - Yves Lévi
- Groupe Santé Publique et Environnement, UMR CNRS 8079 Ecologie Systématique Evolution, Université Paris-Sud, AgroParisTech, Université Paris-Saclay, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France
| | - Philippe M Loiseau
- Chimiothérapie Antiparasitaire, UMR CNRS 8076, BioCIS, Université Paris-Sud, Université Paris-Saclay, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France
| | - Sébastien Pomel
- Chimiothérapie Antiparasitaire, UMR CNRS 8076, BioCIS, Université Paris-Sud, Université Paris-Saclay, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France.
| |
Collapse
|
33
|
Ravichandran V, Kesavan V, Cojean S, Loiseau PM, Jayakrishnan A. Polysorbate Surfactants as Drug Carriers: Tween 20-Amphotericin B Conjugates as Anti-Fungal and Anti-Leishmanial Agents. Curr Drug Deliv 2018; 15:1028-1037. [DOI: 10.2174/1567201815666180503122829] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2017] [Revised: 03/16/2018] [Accepted: 04/16/2018] [Indexed: 11/22/2022]
Affiliation(s)
- Vasanthan Ravichandran
- Biomaterials Laboratory, Department of Biotechnology, Bhupat and Jyothi Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai 600 036, Tamil Nadu, India
| | - Venkitasamy Kesavan
- Biomaterials Laboratory, Department of Biotechnology, Bhupat and Jyothi Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai 600 036, Tamil Nadu, India
| | - Sandrine Cojean
- Chimiotherapie antiparasitaire, UMR 8076 CNRS BioCIS, Faculte de Pharmacie, Universite Paris-Sud, Rue Jean-Baptiste Clement, F-92296, Chatenay-Malabry, France
| | - Philippe M. Loiseau
- Chimiotherapie antiparasitaire, UMR 8076 CNRS BioCIS, Faculte de Pharmacie, Universite Paris-Sud, Rue Jean-Baptiste Clement, F-92296, Chatenay-Malabry, France
| | - A. Jayakrishnan
- Biomaterials Laboratory, Department of Biotechnology, Bhupat and Jyothi Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai 600 036, Tamil Nadu, India
| |
Collapse
|
34
|
Tepshi L, Gupta N, Noel R, Goudet A, Hinsinger K, Michau A, Pons V, Abdelkafi H, Secher T, Shima A, Shtanko O, Sakurai Y, Cojean S, Pomel S, Lievin-Le Moal V, Leignel V, Herweg JA, Fischer A, Johannes L, Harrison K, Beard PM, Rudel T, Vacus J, Loiseau PM, Davey RA, Oswald E, Cintrat JC, Barbier J, Gillet D. Retro-2, a small molecule able to protect cells against a broad spectrum of menacing agents: Toxins, viruses, parasites and intracellular bacteria. Toxicon 2018. [DOI: 10.1016/j.toxicon.2017.12.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Malli S, Bories C, Ponchel G, Loiseau PM, Bouchemal K. Phase solubility studies and anti-Trichomonas vaginalis activity evaluations of metronidazole and methylated β-cyclodextrin complexes: Comparison of CRYSMEB and RAMEB. Exp Parasitol 2018; 189:72-75. [PMID: 29730454 DOI: 10.1016/j.exppara.2018.04.019] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Revised: 04/08/2018] [Accepted: 04/26/2018] [Indexed: 11/28/2022]
Abstract
Metronidazole (MTZ) is a 5-nitroimidazole drug used for the treatment of Trichomonas vaginalis parasitic infection. Aqueous formulations containing MTZ are restricted because apparent solubility in water of this drug is low. In this context, two methylated-β-cyclodextrins (CRYSMEB and RAMEB) were used as a tool to increase apparent solubility of MTZ in water. CRYSMEB was limited by its own solubility in water (15% w/w, 12.59 mM), while RAMEB at a concentration of 40% w/w (300.44 mM) allowed a maximal increase of apparent solubility of MTZ (3.426% w/w, 200.19 mM). From our knowledge, this corresponds to the highest enhancement of MTZ apparent aqueous solubility ever reported in the literature using methylated cyclodextrins. In vitro evaluations showed that anti-T. vaginalis activity of MTZ formulated with CRYSMEB and RAMEB was preserved.
Collapse
Affiliation(s)
- Sophia Malli
- Institut Galien Paris Sud, UMR CNRS 8612, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5, Rue J-B. Clément, 92296, Châtenay-Malabry, France
| | - Christian Bories
- BioCIS « Biomolécules: Conception, Isolement, Synthèse » - « Chimiothérapie Antiparasitaire », UMR CNRS 8076, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5, Rue J.B. Clément, 92296, Châtenay-Malabry Cedex, France
| | - Gilles Ponchel
- Institut Galien Paris Sud, UMR CNRS 8612, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5, Rue J-B. Clément, 92296, Châtenay-Malabry, France
| | - Philippe M Loiseau
- BioCIS « Biomolécules: Conception, Isolement, Synthèse » - « Chimiothérapie Antiparasitaire », UMR CNRS 8076, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5, Rue J.B. Clément, 92296, Châtenay-Malabry Cedex, France
| | - Kawthar Bouchemal
- Institut Galien Paris Sud, Junior Member of the Institut Universitaire de France, UMR CNRS 8612, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5, Rue J-B. Clément, 92296, Châtenay-Malabry, France.
| |
Collapse
|
36
|
Ravichandran V, Kothandaraman GP, Bories C, Loiseau PM, Jayakrishnan A. Synthetic Polysaccharides as Drug Carriers: Synthesis of Polyglucose-Amphotericin B Conjugates and In Vitro Evaluation of Their Anti-Fungal and Anti-Leishmanial Activities. J Nanosci Nanotechnol 2018; 18:2405-2414. [PMID: 29442909 DOI: 10.1166/jnn.2018.14296] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
While many naturally occurring polysaccharides have been widely used as drug carriers, there are two main drawbacks in their use: the first is their physical properties such as molecular weight, branching, type of glycosidic linkages and solubility depend on their source and the method of isolation and purification, the second is many of them are contaminated with proteins and protein removal is essential for preventing immune reactions. Synthetic polysaccharides on the other hand can be tailor made from their respective monomers with consistent physical properties and are, free from protein contamination, both being significant advantages in their use. Although, the synthesis of polysaccharides such as polyglucose, polymannose, polygalactose etc., by the polycondensation of their respective monomers have been reported more than half a century ago, their use as drug carriers have not received any attention so far. In this report, we show that polyglucose (PG) having a weight average molar mass of 37,000 g/mol can be synthesized in a single step by the melt polycondensation of glucose in over 70% yield. Oxidation using sodium periodate generated aldehyde functions on the polymer. Amphotericin B, (AmB) a water-insoluble polyene antibiotic was chosen as a model drug to couple onto periodate oxidized PG via imine linkage at ~20 wt% concentration. The drug loading capacity of the conjugates was above 90%. Further reduction using sodium borohydride gave the more stable amine conjugates with any residual aldehyde on the polymer backbone getting reduced to hydroxyl groups. The conjugates were highly soluble in water and stable on storage. At ten times the concentration of AmB, the conjugates produced negligible hemolysis to human blood. The AmB conjugates were then evaluated for their anti-fungal activity against C. albicans and A. fumigatus and anti-leishmanial activity against different strains of L. donovani in culture. The conjugates showed potent anti-fungal and anti-leishmanial activity. The use of synthetic polysaccharides in drug delivery and in other biomedical applications will have many potential advantages.
Collapse
Affiliation(s)
- Vasanthan Ravichandran
- Biomaterials Laboratory, Department of Biotechnology, Bhupat and Jyothi Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai 600036, Tamil Nadu, India
| | - Gayathri P Kothandaraman
- Biomaterials Laboratory, Department of Biotechnology, Bhupat and Jyothi Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai 600036, Tamil Nadu, India
| | - Christian Bories
- Chimiothérapie Antiparasitaire, UMR 8076 CNRS BioCIS, Faculté de Pharmacie, Université Paris-Sud, 5, Rue Jean-Baptiste Clement, F-92296, Chatenay-Malabry, France
| | - Philippe M Loiseau
- Chimiothérapie Antiparasitaire, UMR 8076 CNRS BioCIS, Faculté de Pharmacie, Université Paris-Sud, 5, Rue Jean-Baptiste Clement, F-92296, Chatenay-Malabry, France
| | - A Jayakrishnan
- Biomaterials Laboratory, Department of Biotechnology, Bhupat and Jyothi Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai 600036, Tamil Nadu, India
| |
Collapse
|
37
|
Jagu E, Pomel S, Diez-Martinez A, Rascol E, Pethe S, Loiseau PM, Labruère R. Synthesis and antikinetoplastid evaluation of bis(benzyl)spermidine derivatives. Eur J Med Chem 2018; 150:655-666. [PMID: 29567458 DOI: 10.1016/j.ejmech.2018.02.087] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Revised: 02/27/2018] [Accepted: 02/28/2018] [Indexed: 01/25/2023]
Abstract
This study describes the synthesis and the biological evaluation of twenty-four original bis(benzyl)spermidines. Structural modifications of the polyamine scaffold were performed in order to avoid easily metabolized bonds. Some bis(benzyl)polyamine derivatives have demonstrated promising activity in vitro against Trypanosoma brucei gambiense and Leishmania donovani. From the enzymatic experiments on trypanothione reductase, we observed that this enzyme was not targeted by our compounds. In vivo evaluation on Swiss mice model infected by T. b. gambiense or L. donovani was done with the most interesting compound of the series.
Collapse
Affiliation(s)
- Elodie Jagu
- Institut de Chimie Moléculaire et des Matériaux d'Orsay (ICMMO), CNRS, Univ Paris Sud, Université Paris-Saclay, 15 rue Georges Clemenceau, 91405 Orsay Cedex, France
| | - Sébastien Pomel
- Chimiothérapie antiparasitaire, UMR 8076 BioCis, CNRS, Univ Paris Sud, Université Paris-Saclay, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France
| | - Alba Diez-Martinez
- Institut de Chimie Moléculaire et des Matériaux d'Orsay (ICMMO), CNRS, Univ Paris Sud, Université Paris-Saclay, 15 rue Georges Clemenceau, 91405 Orsay Cedex, France
| | - Estelle Rascol
- Institut de Chimie Moléculaire et des Matériaux d'Orsay (ICMMO), CNRS, Univ Paris Sud, Université Paris-Saclay, 15 rue Georges Clemenceau, 91405 Orsay Cedex, France
| | - Stéphanie Pethe
- Institut de Chimie Moléculaire et des Matériaux d'Orsay (ICMMO), CNRS, Univ Paris Sud, Université Paris-Saclay, 15 rue Georges Clemenceau, 91405 Orsay Cedex, France
| | - Philippe M Loiseau
- Chimiothérapie antiparasitaire, UMR 8076 BioCis, CNRS, Univ Paris Sud, Université Paris-Saclay, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France.
| | - Raphaël Labruère
- Institut de Chimie Moléculaire et des Matériaux d'Orsay (ICMMO), CNRS, Univ Paris Sud, Université Paris-Saclay, 15 rue Georges Clemenceau, 91405 Orsay Cedex, France.
| |
Collapse
|
38
|
Ravichandran V, Mekarnia N, Pomel S, Cojean S, Ferrié L, Figadère B, Kesavan V, Loiseau PM, Jayakrishnan A. New Water-Soluble Polymeric Prodrugs of 2-n-propylquinoline: Synthesis and Evaluation of In Vitro and In Vivo Activities Against Leishmania donovani. Regen Eng Transl Med 2018. [DOI: 10.1007/s40883-018-0045-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Vásquez-Ocmín P, Cojean S, Rengifo E, Suyyagh-Albouz S, Amasifuen Guerra CA, Pomel S, Cabanillas B, Mejía K, Loiseau PM, Figadère B, Maciuk A. Antiprotozoal activity of medicinal plants used by Iquitos-Nauta road communities in Loreto (Peru). J Ethnopharmacol 2018; 210:372-385. [PMID: 28887215 DOI: 10.1016/j.jep.2017.08.039] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 08/17/2017] [Accepted: 08/29/2017] [Indexed: 06/07/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE In the Peruvian Amazon, the use of medicinal plants is a common practice. However, there is few documented information about the practical aspects of their use and few scientific validation. The starting point for this work was a set of interviews of people living in rural communities from the Peruvian Amazon about their uses of plants. Protozoan diseases are a public health issue in the Amazonian communities, who partly cope with it by using traditional remedies. Validation of these traditional practices contributes to public health care efficiency and may help identify new antiprotozoal compounds. AIMS OF STUDY to inventory and validate the use of medicinal plants by rural people of Loreto region. MATERIALS AND METHODS Rural mestizos were interviewed about traditional medication of parasite infections with medicinal plants. Ethnopharmacological surveys were undertaken in two villages along Iquitos-Nauta road (Loreto region, Peru), namely 13 de Febrero and El Dorado communities. Forty-six plants were collected according to their traditional use for the treatment of parasitic diseases, 50 ethanolic extracts (different parts for some of the plants) were tested in vitro on Plasmodium falciparum (3D7 sensitive strain and W2 chloroquine resistant strain), Leishmania donovani LV9 strain and Trypanosoma brucei gambiense. Cytotoxic assessment (HUVEC cells) of the active extracts was performed. Two of the most active plants were submitted to preliminary bioguided fractionation to ascertain and explore their activities. RESULTS From the initial plants list, 10 were found to be active on P. falciparum, 15 on L. donovani and 2 on the three parasites. The ethanolic extract from Costus curvibracteatus (Costaceae) leaves and Grias neuberthii (Lecythidaceae) bark showed strong in vitro activity on P. falciparum (sensitive and resistant strain) and L. donovani and moderate activity on T. brucei gambiense. CONCLUSIONS The Amazonian forest communities in Peru represents a source of knowledge on the use of medicinal plants. In this work, several extracts with antiprotozoal activity were identified. This work contributes to validate some traditional uses and opens subsequent investigations on active compounds isolation and identification.
Collapse
Affiliation(s)
- Pedro Vásquez-Ocmín
- Equipe "Chimie des substances naturelles" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 5 rue J.-B. Clément, 92290 Châtenay-Malabry, France.
| | - Sandrine Cojean
- Equipe "Chimiothérapie antiparasitaire" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 5 rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Elsa Rengifo
- Instituto de Investigaciones de la Amazonía Peruana, Avenida Abelardo Quiñonez Km. 4.5, Iquitos, Peru
| | - Soulaf Suyyagh-Albouz
- Equipe "Chimiothérapie antiparasitaire" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 5 rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Carlos A Amasifuen Guerra
- Universidad Nacional de la Amazonía Peruana, Facultad de Ciencias Forestales, Calle Pevas 5ta cuadra, Iquitos, Peru
| | - Sébastien Pomel
- Equipe "Chimiothérapie antiparasitaire" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 5 rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Billy Cabanillas
- Instituto de Investigaciones de la Amazonía Peruana, Avenida Abelardo Quiñonez Km. 4.5, Iquitos, Peru
| | - Kember Mejía
- Instituto de Investigaciones de la Amazonía Peruana, Avenida Abelardo Quiñonez Km. 4.5, Iquitos, Peru
| | - Philippe M Loiseau
- Equipe "Chimiothérapie antiparasitaire" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 5 rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Bruno Figadère
- Equipe "Chimie des substances naturelles" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 5 rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Alexandre Maciuk
- Equipe "Chimie des substances naturelles" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 5 rue J.-B. Clément, 92290 Châtenay-Malabry, France.
| |
Collapse
|
40
|
Taravaud A, Loiseau PM, Pomel S. In vitro evaluation of antimicrobial agents on Acanthamoeba sp. and evidence of a natural resilience to amphotericin B. Int J Parasitol Drugs Drug Resist 2017; 7:328-336. [PMID: 28918001 PMCID: PMC5604952 DOI: 10.1016/j.ijpddr.2017.09.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/23/2017] [Revised: 09/01/2017] [Accepted: 09/07/2017] [Indexed: 12/11/2022]
Abstract
The free-living amoeba (FLA) Acanthamoeba sp. is an opportunistic pathogen that can cause amoebic keratitis (AK) or granulomatous amoebic encephalitis (GAE). While current treatments of AK are long with some relapses, no consensus therapy has been developed for GAE remaining lethal in 90% of the cases. In this context, efficient antiacanthamoebal drugs have to be identified. In this work, 15 drugs used in the treatment of AK or GAE or in other parasitic diseases were evaluated for their in vitro activity on A. castellanii. Hexamidine, voriconazole and clotrimazole exhibited the highest activities with IC50 values at 0.05 μM, 0.40 μM and 0.80 μM, respectively, while rifampicin, metronidazole and cotrimoxazole were inactive. Among 15 drug associations evaluated, no synergistic effect was observed, and one antagonism was determined between hexamidine and chlorhexidine. Interestingly, amphotericin B was the only drug presenting an increase of IC50 as a function of treatment duration. The amoebae susceptibility to amphotericin B cultured in the presence of 250 μM of the drug was similar to the one of a naive control, revealing that no resistant strain could be selected. However, the amoebae susceptibility always returned to an initial level at each passage. This natural and non-acquired adaptation to amphotericin B, qualified as resilience, was observed in several strains of A. castellanii and A. polyphaga. Using a pharmacological approach with effectors of different cellular mechanisms or transports, and an ultrastructural analysis of amphotericin B-treated amoebae, the involvement of several mitochondria-dependent pathways as well as multidrug resistant transporters was determined in amphotericin B resilience. Based on the observations from this study, the relevance of using amphotericin B in GAE treatments may be reconsidered, while the use of some other drugs, such as rifampicin or cotrimoxazole, is not relative to intrinsic antiacanthamoebal activity. In vitro evaluation of 15 antimicrobial agents on Acanthamoeba castellanii. Best activity for hexamidine and inefficiency of rifampicin and cotrimoxazole. Antagonism of the combination chlorhexidine/hexamidine. Natural resilience of Acanthamoeba sp. for amphotericin B. Involvement of mitochondria-dependent pathways and MDR in amphotericin B resilience.
Collapse
Affiliation(s)
- Alexandre Taravaud
- Chimiothérapie Antiparasitaire, UMR CNRS 8076, BioCIS, Université Paris-Sud, Université Paris-Saclay, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France
| | - Philippe M Loiseau
- Chimiothérapie Antiparasitaire, UMR CNRS 8076, BioCIS, Université Paris-Sud, Université Paris-Saclay, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France
| | - Sébastien Pomel
- Chimiothérapie Antiparasitaire, UMR CNRS 8076, BioCIS, Université Paris-Sud, Université Paris-Saclay, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France.
| |
Collapse
|
41
|
Komlaga G, Genta-Jouve G, Cojean S, Dickson RA, Mensah ML, Loiseau PM, Champy P, Beniddir MA. Antiplasmodial Securinega alkaloids from Phyllanthus fraternus: Discovery of natural (+)-allonorsecurinine. Tetrahedron Lett 2017. [DOI: 10.1016/j.tetlet.2017.08.045] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
42
|
Kothandaraman GP, Ravichandran V, Bories C, Loiseau PM, Jayakrishnan A. Anti-fungal and anti-leishmanial activities of pectin-amphotericin B conjugates. J Drug Deliv Sci Technol 2017. [DOI: 10.1016/j.jddst.2017.02.010] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
43
|
Fox Ramos AE, Alcover C, Evanno L, Maciuk A, Litaudon M, Duplais C, Bernadat G, Gallard JF, Jullian JC, Mouray E, Grellier P, Loiseau PM, Pomel S, Poupon E, Champy P, Beniddir MA. Revisiting Previously Investigated Plants: A Molecular Networking-Based Study of Geissospermum laeve. J Nat Prod 2017; 80:1007-1014. [PMID: 28282127 DOI: 10.1021/acs.jnatprod.6b01013] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Three new monoterpene indole alkaloids (1-3) have been isolated from the bark of Geissospermum laeve, together with the known alkaloids (-)-leuconolam (4), geissolosimine (5), and geissospermine (6). The structures of 1-3 were elucidated by analysis of their HRMS and NMR spectroscopic data. The absolute configuration of geissolaevine (1) was deduced from the comparison of experimental and theoretically calculated ECD spectra. The isolation workflow was guided by a molecular networking-based dereplication strategy using an in-house database of monoterpene indole alkaloids. In addition, five known compounds previously undescribed in the Geissospermum genus were dereplicated from the G. laeve alkaloid extract network and were assigned with various levels of identification confidence. The antiparasitic activities against Plasmodium falciparum and Leishmania donovani as well as the cytotoxic activity against the MRC-5 cell line were determined for compounds 1-5.
Collapse
Affiliation(s)
- Alexander E Fox Ramos
- Équipe "Pharmacognosie-Chimie des Substances Naturelles" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay , 5 Rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Charlotte Alcover
- Équipe "Pharmacognosie-Chimie des Substances Naturelles" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay , 5 Rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Laurent Evanno
- Équipe "Pharmacognosie-Chimie des Substances Naturelles" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay , 5 Rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Alexandre Maciuk
- Équipe "Pharmacognosie-Chimie des Substances Naturelles" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay , 5 Rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Marc Litaudon
- Institut de Chimie des Substances Naturelles, CNRS, ICSN UPR 2301, Université Paris-Saclay , 21 Avenue de la Terrasse, 91198 Gif-sur-Yvette, France
| | - Christophe Duplais
- CNRS, UMR8172 EcoFoG, AgroParisTech, Cirad, INRA, Université des Antilles, Université de Guyane , 23 Avenue Pasteur, 97300 Cayenne, France
| | - Guillaume Bernadat
- Équipe "Molécules Fluorées et Chimie Médicinale" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay , 5 rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Jean-François Gallard
- Institut de Chimie des Substances Naturelles, CNRS, ICSN UPR 2301, Université Paris-Saclay , 21 Avenue de la Terrasse, 91198 Gif-sur-Yvette, France
| | - Jean-Christophe Jullian
- Équipe "Pharmacognosie-Chimie des Substances Naturelles" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay , 5 Rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Elisabeth Mouray
- Unité Molécules de Communication et Adaptation des Microorganismes (MCAM, UMR 7245), Muséum National d'Histoire Naturelle, CNRS, Sorbonne Universités, CP52 , 57 Rue Cuvier, 75005 Paris, France
| | - Philippe Grellier
- Unité Molécules de Communication et Adaptation des Microorganismes (MCAM, UMR 7245), Muséum National d'Histoire Naturelle, CNRS, Sorbonne Universités, CP52 , 57 Rue Cuvier, 75005 Paris, France
| | - Philippe M Loiseau
- Équipe "Chimiothérapie Antiparasitaire" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay , 5 Rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Sébastien Pomel
- Équipe "Chimiothérapie Antiparasitaire" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay , 5 Rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Erwan Poupon
- Équipe "Pharmacognosie-Chimie des Substances Naturelles" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay , 5 Rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Pierre Champy
- Équipe "Pharmacognosie-Chimie des Substances Naturelles" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay , 5 Rue J.-B. Clément, 92290 Châtenay-Malabry, France
| | - Mehdi A Beniddir
- Équipe "Pharmacognosie-Chimie des Substances Naturelles" BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay , 5 Rue J.-B. Clément, 92290 Châtenay-Malabry, France
| |
Collapse
|
44
|
Malli S, Bories C, Pradines B, Loiseau PM, Ponchel G, Bouchemal K. In situ forming pluronic® F127/chitosan hydrogel limits metronidazole transmucosal absorption. Eur J Pharm Biopharm 2017; 112:143-147. [DOI: 10.1016/j.ejpb.2016.11.024] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Revised: 11/11/2016] [Accepted: 11/16/2016] [Indexed: 11/28/2022]
|
45
|
Grisin T, Bories C, Loiseau PM, Bouchemal K. Cyclodextrin-mediated self-associating chitosan micro-platelets act as a drug booster against Candida glabrata mucosal infection in immunocompetent mice. Int J Pharm 2017; 519:381-389. [DOI: 10.1016/j.ijpharm.2017.01.048] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2016] [Revised: 01/19/2017] [Accepted: 01/23/2017] [Indexed: 10/20/2022]
|
46
|
Jagu E, Pomel S, Diez-Martinez A, Ramiandrasoa F, Krauth-Siegel RL, Pethe S, Blonski C, Labruère R, Loiseau PM. Synthesis and in vitro antikinetoplastid activity of polyamine–hydroxybenzotriazole conjugates. Bioorg Med Chem 2017; 25:84-90. [DOI: 10.1016/j.bmc.2016.10.013] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2016] [Revised: 09/20/2016] [Accepted: 10/10/2016] [Indexed: 11/29/2022]
|
47
|
Gupta N, Noël R, Goudet A, Hinsinger K, Michau A, Pons V, Abdelkafi H, Secher T, Shima A, Shtanko O, Sakurai Y, Cojean S, Pomel S, Liévin-Le Moal V, Leignel V, Herweg JA, Fischer A, Johannes L, Harrison K, Beard PM, Clayette P, Le Grand R, Rayner JO, Rudel T, Vacus J, Loiseau PM, Davey RA, Oswald E, Cintrat JC, Barbier J, Gillet D. Inhibitors of retrograde trafficking active against ricin and Shiga toxins also protect cells from several viruses, Leishmania and Chlamydiales. Chem Biol Interact 2016; 267:96-103. [PMID: 27712998 DOI: 10.1016/j.cbi.2016.10.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2016] [Revised: 08/09/2016] [Accepted: 10/03/2016] [Indexed: 11/25/2022]
Abstract
Medical countermeasures to treat biothreat agent infections require broad-spectrum therapeutics that do not induce agent resistance. A cell-based high-throughput screen (HTS) against ricin toxin combined with hit optimization allowed selection of a family of compounds that meet these requirements. The hit compound Retro-2 and its derivatives have been demonstrated to be safe in vivo in mice even at high doses. Moreover, Retro-2 is an inhibitor of retrograde transport that affects syntaxin-5-dependent toxins and pathogens. As a consequence, it has a broad-spectrum activity that has been demonstrated both in vitro and in vivo against ricin, Shiga toxin-producing O104:H4 entero-hemorrhagic E. coli and Leishmania sp. and in vitro against Ebola, Marburg and poxviruses and Chlamydiales. An effect is anticipated on other toxins or pathogens that use retrograde trafficking and syntaxin-5. Since Retro-2 targets cell components of the host and not directly the pathogen, no selection of resistant pathogens is expected. These lead compounds need now to be developed as drugs for human use.
Collapse
Affiliation(s)
- Neetu Gupta
- Institute of Biology and Technology of Saclay (IBITECS), CEA, LabEx LERMIT, Université Paris-Saclay, F-91191, Gif Sur Yvette, France
| | - Romain Noël
- Institute of Biology and Technology of Saclay (IBITECS), CEA, LabEx LERMIT, Université Paris-Saclay, F-91191, Gif Sur Yvette, France
| | - Amélie Goudet
- Institute of Biology and Technology of Saclay (IBITECS), CEA, LabEx LERMIT, Université Paris-Saclay, F-91191, Gif Sur Yvette, France
| | - Karen Hinsinger
- Institute of Biology and Technology of Saclay (IBITECS), CEA, LabEx LERMIT, Université Paris-Saclay, F-91191, Gif Sur Yvette, France
| | - Aurélien Michau
- Institute of Biology and Technology of Saclay (IBITECS), CEA, LabEx LERMIT, Université Paris-Saclay, F-91191, Gif Sur Yvette, France
| | - Valérie Pons
- Institute of Biology and Technology of Saclay (IBITECS), CEA, LabEx LERMIT, Université Paris-Saclay, F-91191, Gif Sur Yvette, France
| | - Hajer Abdelkafi
- Institute of Biology and Technology of Saclay (IBITECS), CEA, LabEx LERMIT, Université Paris-Saclay, F-91191, Gif Sur Yvette, France
| | | | | | - Olena Shtanko
- Texas Biomedical Research Institute, San Antonio, TX, USA
| | | | - Sandrine Cojean
- Antiparasitic Chemotherapy, UMR 8076, CNRS BioCIS, LabEx LERMIT, Université Paris-Sud, Université Paris-Saclay, F-92290, Chatenay-Malabry, France
| | - Sébastien Pomel
- Antiparasitic Chemotherapy, UMR 8076, CNRS BioCIS, LabEx LERMIT, Université Paris-Sud, Université Paris-Saclay, F-92290, Chatenay-Malabry, France
| | - Vanessa Liévin-Le Moal
- Antiparasitic Chemotherapy, UMR 8076, CNRS BioCIS, LabEx LERMIT, Université Paris-Sud, Université Paris-Saclay, F-92290, Chatenay-Malabry, France
| | - Véronique Leignel
- DRUGABILIS (French Research Performer SME), F-92290, Chatenay-Malabry, France
| | - Jo-Ana Herweg
- University of Würzburg, Biocenter, Chair of Microbiology, Am Hubland, D-97074, Würzburg, Germany
| | - Annette Fischer
- University of Würzburg, Biocenter, Chair of Microbiology, Am Hubland, D-97074, Würzburg, Germany
| | - Ludger Johannes
- Institut Curie, PSL Research University, Endocytic Trafficking and Therapeutic Delivery Group, 26 rue d'Ulm, F-75248, Paris Cedex 05, France; CNRS, UMR3666, F-75005, Paris, France; INSERM, U1143, F-75005, Paris, France
| | - Kate Harrison
- The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Roslin, Midlothian, EH25 9RG, United Kingdom
| | - Philippa M Beard
- The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Roslin, Midlothian, EH25 9RG, United Kingdom; The Pirbright Institute, Ash Rd, Pirbright, Surrey GH24 0NF, United Kingdom
| | - Pascal Clayette
- ImmunoPharmacology and Biosafety Laboratory, BERTIN Pharma, CEA, F-92265, Fontenay-aux-Roses, France
| | - Roger Le Grand
- Institute of Emerging Diseases and Innovative Therapies, CEA, U1184, Immunology of Viral Infections and Autoimmune Diseases, Infectious Disease Models and Innovative Therapies Infrastructure, F-92265, Fontenay-aux-Roses, France; INSERM, U1184, F-94276, Le Kremlin-Bicêtre, France; University of Paris South, U1184, F-92265, Fontenay-aux-Roses, France; Vaccine Research Institute, Henri Mondor Hospital, F-94010, Créteil, France
| | - Jonathan O Rayner
- Infectious Disease Research, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
| | - Thomas Rudel
- University of Würzburg, Biocenter, Chair of Microbiology, Am Hubland, D-97074, Würzburg, Germany
| | - Joël Vacus
- DRUGABILIS (French Research Performer SME), F-92290, Chatenay-Malabry, France
| | - Philippe M Loiseau
- Antiparasitic Chemotherapy, UMR 8076, CNRS BioCIS, LabEx LERMIT, Université Paris-Sud, Université Paris-Saclay, F-92290, Chatenay-Malabry, France
| | - Robert A Davey
- Texas Biomedical Research Institute, San Antonio, TX, USA
| | | | - Jean-Christophe Cintrat
- Institute of Biology and Technology of Saclay (IBITECS), CEA, LabEx LERMIT, Université Paris-Saclay, F-91191, Gif Sur Yvette, France
| | - Julien Barbier
- Institute of Biology and Technology of Saclay (IBITECS), CEA, LabEx LERMIT, Université Paris-Saclay, F-91191, Gif Sur Yvette, France
| | - Daniel Gillet
- Institute of Biology and Technology of Saclay (IBITECS), CEA, LabEx LERMIT, Université Paris-Saclay, F-91191, Gif Sur Yvette, France.
| |
Collapse
|
48
|
Komlaga G, Cojean S, Dickson RA, Beniddir MA, Suyyagh-Albouz S, Mensah MLK, Agyare C, Champy P, Loiseau PM. Antiplasmodial activity of selected medicinal plants used to treat malaria in Ghana. Parasitol Res 2016; 115:3185-95. [DOI: 10.1007/s00436-016-5080-8] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Accepted: 04/19/2016] [Indexed: 11/29/2022]
|
49
|
Morais ARDV, Júnior FHX, Alencar ÉDN, Loiseau PM, Barratt G, Fessi H, Elaissari A, Egito ESTD. Freeze-Dried Microemulsion Containing Amphotericin B for Leishmaniasis Treatment: An Overview. ACTA ACUST UNITED AC 2016. [DOI: 10.1166/jcsb.2016.1136] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
50
|
Liévin-Le Moal V, Loiseau PM. Leishmania hijacking of the macrophage intracellular compartments. FEBS J 2015; 283:598-607. [PMID: 26588037 DOI: 10.1111/febs.13601] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Revised: 11/08/2015] [Accepted: 11/13/2015] [Indexed: 12/15/2022]
Abstract
Leishmania spp., transmitted to humans by the bite of the sandfly vector, are responsible for the three major forms of leishmaniasis, cutaneous, diffuse mucocutaneous and visceral. Leishmania spp. interact with membrane receptors of neutrophils and macrophages. In macrophages, the parasite is internalized within a parasitophorous vacuole and engages in a particular intracellular lifestyle in which the flagellated, motile Leishmania promastigote metacyclic form differentiates into non-motile, metacyclic amastigote form. This phenomenon is induced by Leishmania-triggered events leading to the fusion of the parasitophorous vacuole with vesicular members of the host cell endocytic pathway including recycling endosomes, late endosomes and the endoplasmic reticulum. Maturation of the parasitophorous vacuole leads to the intracellular proliferation of the Leishmania amastigote forms by acquisition of host cell nutrients while escaping host defense responses.
Collapse
Affiliation(s)
- Vanessa Liévin-Le Moal
- Anti-Parasitic Chemotherapy, Faculté de Pharmacie, CNRS, UMR 8076 BioCIS, Châtenay-Malabry, France.,Université Paris-Sud, Orsay, France.,Faculté de Pharmacie, Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LabEx LERMIT), Châtenay-Malabry, France
| | - Philippe M Loiseau
- Anti-Parasitic Chemotherapy, Faculté de Pharmacie, CNRS, UMR 8076 BioCIS, Châtenay-Malabry, France.,Université Paris-Sud, Orsay, France.,Faculté de Pharmacie, Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LabEx LERMIT), Châtenay-Malabry, France
| |
Collapse
|